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CYCLIN E INDUCTION AND ONCOLYTIC REPLICATION OF E1B-DELETED 
ADENOVIRUSES 
 
Pei-Hsin Cheng  
November 22, 2013 
 
Virus-mediated oncolysis has been considered as a new and promising cancer 
therapeutic approach. Although adenoviruses (Ads) with deletion of E1b55K 
preferentially replicate in cancer cells and have been used in numerous cancer 
treatments, the selective replication mechanism of this kind of virus still remains 
controversial. The lack of a well-established studies focusing on possible 
mechanisms enabling tumor selectivity of oncolytic Ads has hindered the further 
development of virotherapies and limits their clinical applications. Therefore, 
uncovering the molecular basis behind the tumor-killing phenomena will fill critical 
gaps in our understanding of the oncolytic adenovirology. Previously our 
laboratory has demonstrated that Ad E1B55K protein is involved in cyclin E 
induction that is required for efficient virus replication. However, functional 
E1B55K expression is not required for oncolytic Ad replication in cancer cells, 
many of which have deregulated cyclin E overexpression. In this dissertation we 
advanced the previous findings to further develop the mechanism model of 
selective oncolytic replication of E1b-deleted Ads, and then applied these insights 
viii 
to design a novel tumor-specific oncolytic Ad vector. We demonstrated that 
Ad-induced cyclin E subsequently activates CDK2 that targets the transcriptional 
suppressor pRb to generate a cellular environment for productive viral replication. 
Based on this understanding, a novel tumor-specific oncolytic vector, Ad-cycE, 
was developed in which the cyclin E promoter was used to control a critical 
regulatory viral E1a gene. As cyclin E is greatly induced in cancer cells after Ad 
transduction, Ad-cycE shows significant oncolytic efficacy in vitro and strongly 
repressed tumor growth in vivo. Additional work has been completed exploring the 
impact of using a combination treatment of Ad-cycE and rapamycin which induces 
autophagy; the results indicated a synergistic antitumor effect that was statistically 
significant. This work has advanced our knowledge of the cancer selectivity of 
E1b-deleted Ads, and will lead to further progress in the field of oncolytic 
virotherapy. 
ix 
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1.1. Oncolytic virotherapy 
Cancer is the most common cause of death in the world (1). The limitations of 
currently available therapies demand the continued development of more potent 
cancer treatment options. Oncolytic virotherapy represents a fast growing 
therapeutic platform for cancer treatment (2, 3). The therapeutic effects emanate 
from a relatively small amount of virus, which preferentially replicates in and lyses 
cancer cells. This is followed by a localized spread to the surrounding tumor cells, 
ultimately leading to reduction of the tumor mass (4). Current oncolytic viruses, 
including adenovirus (Ad), herpes simplex virus, measles virus, newcastle 
disease virus, reovirus, parovirus, poliovirus, seneca valley virus, retrovirus, 
vaccinia, and vesicular stomatitis virus, have been tested in numerous preclinical 
or clinical settings (5). Although many viruses have already been developed, Ads 
are still the most commonly used oncolytic vectors for gene therapy due to their 
infection efficacy, high titer production, safety, easy genetic modification and 
well-studied replication characteristics (6).   
 
1.2. Human adenovirus 
Human adenoviruses, as a common cause of respiratory tract diseases, are 
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nonevenloped DNA viruses which can infect cells at many different cell cycle 
stages without integrating into host cellular chromosomes (7). Adenovirus 
serotype 5 (group C) have been wildely used in oncolytic virotherapy due to the 
favorable safety profile and only cause clinical disease in patients by producing 
negligible flu-like symptoms such as fever, myalgias, asthenia and chills (8, 18). 
Generalized Ad structure and viral genome map were depicted in Figure 1.1. The 
viral genome is composed of a linear, double-stranded DNA of approximately 36 
Kb and can be divided into early (E) and late (L) genes (7, 9). The E1 genes 
encode critical proteins including E1a and E1b for the initiation and regulation of 
viral and cellular gene expression. The E2 genes encode three different proteins 
which function directly in viral DNA replication, while the E3 genes encode 
proteins which can modulate infected host immune responses. Products of the E4 
genes encode proteins of diverse functions such as regulating viral gene 
transcription, translation, mRNA nuclear export and apoptosis pathways. The L 
genes encode structural proteins for packaging the viral genome into virion 
































Figure 1.1. Generalized structure and genome map of adenovirus serotype 5. 
Major structural components of a wild-type Ad capsid include hexon, penton base, 
and fiber structures. Adenovirus capsids enclose a 36 Kb double-stranded DNA 
genome, shown as the red line inside the capsids. The inverted terminal repeat 
(ITR), the packaging signal (Ψ) and major late promoter (MLP) are indicated. The 
solid lines represent viral genome and the white line represents the deleted region. 
Early transcripts are represented by E1-E4 regions and late transcripts are 
represented by L1-L5 regions. E1 region contains E1A and E1B regions. The 
E1B19K and E1B55K in E1B region have a small overlap. 
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The Ad infection begins by binding of knob domain on the adenovirus fiber to a 
specific coxsackievirus and adenovirus receptor (CAR) located on the cell surface; 
this interaction facilitates the entry of virus into the host cells by endocytosis. The 
low-pH environment of the endosome allows the viral capsid to disassociate, 
resulting in the release of virions from the endosome (10-12). By cooperating with 
microtubules, virions are then transported to the nuclear pore complex where the 
virions disassemble and the double-stranded viral DNA is released to directly 
enter the nucleus.  
 
The replication of Ads relies on utilizing the cellular components as building blocks. 
The replication cycle of Ads is divided into two phases based on the onset of viral 
gene expression (7). The early phase includes the expression of a set of viral 
genes to promote cellular entry into an S-like phase, block apoptosis, and prevent 
cellular immune responses. After the early gene products adjust the replication 
machinery and other critical cellular components inside host cells, the gene 
expression transitions to the late phase, in which adenoviral DNA replicates and 
the structural proteins are synthesized. Once adenoviruses have finished the 
amplification of their DNA and synthesis of their structural proteins, then viral 
assembly can take place producing virions. Viral replication subsequently cause 
cell lysis and release of progeny virions from the infected cells, leading to 
significant amplification of the Ads which produces up to 10,000 viral particles per 
cell (7, 13). 
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1.3. E1b55K-deleted oncolytic adenoviruses 
The idea of treating cancers with the adenoviruses began in the 1950s (5, 14). 
Wild-type Ad5 was injected in thirty patients with epidermoid cervical carcinomas 
and 65% of the virus injections induced necrosis in the tumors without causing 
severe toxicity. While producing some promising results, the long-term safety 
concerns, limited final therapeutic efficacy and tumor recurrence after the 
treatment was completed prevented further development of this approach until 
recently. A novel gene-attenuated oncolytic adenovirus dl1520 (ONYX-015) was 
designed with an 827-bp deletion in the E1b region and a point mutation which 
generates a premature stop codon to prevent the expression of its E1B55K 
protein (Fig 1.1) (15-17). This new virus dl1520 showed potent and promising 
oncolytic efficacy in several preclinical studies and became the first oncolytic 
adenovirus used in the clinical trials in United States since 1996, treating 
approximately 200-300 cancer patients with various routes of administration in 
more than ten clinical trials (from phase I to II) (17, 18). However, during a phase 
III clinical trial in 2003, when treatment with dl1520 was combined with 
chemotherapy in patients with head and neck squamous cell carcinoma the trial 
was suspended due to limited therapeutic potential in metastatic cancer patients 
(18).  
H101 (Oncorine) is another oncolytic adenovirus similar to dl1520 generated by 
the Chinese company, Sunway Biotech (18, 19). The phase I clinical trial with 
H101 as a single therapeutic agent began in 2000 in China and the phase II and 
III trials of H101 in combination with chemotherapy started from 2001 to 2004. 
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Overall, the clinical tolerability and responses of H101 treatment have been very 
promising (18, 19). The rights to dl1520 were bought by Sunway Biotech which 
has completed Phase III clinical studies. More than 600 cancer patients have 
safely received the treatment with H101 in clinical trials in China (18, 20). The 
company reported a 79% positive response rate for H101 plus chemotherapy as 
compared with 40% for chemotherapy alone (21). Considering the impact of these 
results, the Chinese State Food and Drug Administration approved H101 for use 
in combination with chemotherapy for the treatment of late-stage cancers. 
Therefore, Sunway Biotech has marketed H101 for treating head and neck 
cancers (21, 22). Besides H101, this company has also developed other 
genetically modified oncolytic adenoviruses H102 and H103 for cancer treatment 
(23). H102 virus replication is driven by the alpha-fetoprotein promoter which 
specifically targets primary hepatocellular carcinoma, and is currently in the 
preclinical stage of development. H103 is an oncolytic adenovirus carrying a 
tumor antigen known as heat shock protein (HSP) 70 gene which can stimulate an 
antitumor immune response while the virus selectively replicates within tumor 
cells. A phase I clinical trial of intratumoral injection of H103 has been conducted 
in a total of 27 patients with advanced stage solid tumors; an 11.1% objective 
response (cases with complete response + partial response) to H103-injected 
tumors and a 48.1% clinical benefit rate (cases with complete response + partial 




Currently various oncolytic adenoviruses have been reported in preclinical studies 
and at least ten of these have been active or approved for human clinical trials (3, 
5). Examples include Ad-OC-E1a (24), Ad5-CD/TKrep (25, 26), Ad-delta24-RGD 
(27, 28), CG7060 (CV706) (29), CG7870 (CV787) (30), CG0070 (31), Telomelysin 
(OBP-301) (32), CGTG-102 (33), H103 (20), KH901 (34) and ICOVIR-5 (currently 
recruiting patients, Clinicaltrials.gov identifier: NCT01864759). These vectors 
were constructed based on the deletion of critical viral genes combined with 
multiple strategies such as transcriptionally targeting cancer cells with 
tumor-specific promoters, or transductionally targeting cancers with modification 
on various viral capsid proteins, or arming the vectors with immune stimulating 
genes (35). Nevertheless H101 is the only oncolytic adenovirus that has been 
commercially approved for clinical application in China, but not in the other 
countries.  
 
1.4. Molecular mechanisms of E1b55K-deleted Ad selectivity in cancer cells 
Even though E1b55K-deleted oncolytic Ads have been used in several clinical 
trials and is marketed in China, the mechanism(s) enabling this oncolytic 
selectivity, remains controversial. The following sections summarize three 
proposed mechanisms. 
 
1.4.1. Cancer selectivity of E1b55K-deleted Ads based on p53 deficiency  
The original mechanism proposed that E1b55K-deleted oncolytic Ad could only 
replicate in p53-deficient tumor cells, but not in normal cells with functional p53 
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(Fig. 1.2) (16, 17, 36). After virus infection, Ad E1A is expressed immediately to 
regulate expression of viral genes and promote transduced cell entry into an 
S-like cell cycle phase (37). In response to Ad infection, host cells have developed 
a crucial strategy to block the virus spread by activation of p53-mediated 
apoptosis and cell-cycle arrest after Ad infection and E1A expression (7, 38, 39). 
Ad E1A triggers the accumulation of p53 protein either by activating p53 
transcription, (40) or stabilizing p53 via inducing expression of p14ARF tumor 
suppressor (referred to as p19ARF in murine cells) which binds to MDM2 protein 
and subsequently blocks MDM2-induced p53 degradation and transactivational 
silencing (41-43). Consequently, high levels of p53 in infected cells lead to either 
cell-cycle arrest or apoptosis to block viral replication and spread.  
 
In response to this, Ad has developed its ways to overcome p53-mediated 
apoptosis and cell-cycle arrest triggered by Ad infection. It was reported that Ad 
E1B55K protects the infected cells from the E1A-induced p53 effects through at 
least three distinct mechanisms. First, E1B55K binds to the amino terminus of p53, 
and thus represses p53 transactivation (44, 45). Second, E1B55K cooperates 
with Ad E4orf6 to proteolytically degrade p53 (46-48). Third, E1B55K alone can 
function as an E3 SUMO1-p53 ligase eventually also leading to p53 
polyubiquitinylation and proteasomal degradation (49). Therefore in normal cells, 
E1B55K counteracts the p53-dependent apoptosis induction by E1A and prevents 
premature cell death, resulting in efficient viral replication (44, 45). Without 
E1B55K protein, E1b55K-deleted Ads were considered to not be able to 
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counteract E1A-induced p53 accumulation and thus fail to replicate in normal cells 
with functional p53 protein. Deficiency of p53 occurs frequently in many types of 
human cancers due to p53 gene deletion or mutation (50, 51). Since cancer cells 
typically lack functional p53 protein or its pathways, the E1B55K function of 
inhibiting p53 is not as important as it is in normal cells and thus it was proposed 
that dl1520 could selectively replicate in cancer cells with dysfunctional p53 
pathways (16, 17). 
 
While some reports have supported the hypothesis that E1b55K-deleted Ads 
selectively kill cancer cells with p53 deficiency, the original mechanism has been 
challenged by several studies. Studies in our laboratory and others' have shown 
E1b55K-deleted Ads are able to replicate in and kill cancer cells with wild-type 
p53 as efficiently as in cancer cells with p53 deficiency (52-56). To resolve this 
paradox, it was proposed that either p53 deficiency or p14ARF deficiency might 
determine the cancer selectivity of E1b55K-deleted Ads (57, 58). In cancer cells 
with wild-type p53, loss of the functional p14ARF would neutralize MDM2-mediated 
p53 degradation and was considered to prevent p53 from its normal functions. 
Thus p14ARF deficiency in cancer cells was indicated as the alternative molecular 
mechanism to allow dl1520 replication in these cancer cells with wild-type p53. 
However, experimental data contradicted this mechanism by showing that in 
several cancer cell lines the replication of dl1520 is not controlled by the p53 or 
p14ARF status (59). 
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Also, it has been reported that in some cell lines, p53 can promote the viral lytic 
cycle and may be required for productive virus replication and late viral gene 
expression by cooperating with E1A to enhance transcription at the major late 
gene promoter of the virus genome (60, 61). Further studies also revealed that 
accumulation of p53 induced by E1b55K-deleted or E1b55K-mutated Ads can 
neither efficiently induce apoptosis nor activate the transcription of downstream 
p53-responsive genes in Ad-infected primary cells (62, 63). Moreover, in cells 
which are infected with E1b55K-deleted Ads, E1b19K, as a homologue of BCL-2 
family members, can also function as an inhibitor to adenovirus E1A 
protein-induced apoptosis (38). Even if E1A-induced apoptosis occurs in 
Ad-infected cancer cells, it does not prevent the replication of E1b-deleted 
oncolytic Ads in the majority of cells (38). Thereby, blocking p53 activity may not 
be the major requirement for viral replication, and p53 deficiency in cancer cells 
seems unlikely to be the determinant of oncolytic selectivity of E1b55K-deleted 
Ads.  
 
So far none of the comprehensive research has been reported to sort out the 
controversy existing between this mechanism model and currently available 
literature. The lack of new experimental data to support the original hypothesis 
hence raises the concern that the mechanism of cancer selectivity of 
E1b55K-deleted oncolytic Ads has to be further addressed. 
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Figure 1.2. Proposed mechanism that oncolytic selectivity of 
E1b55K-deleted Ads depends on p53 deficiency in cancer cells. E1B55K is 
reported to inhibit p53 function, which prevents cellular p53-dependent apoptosis 
induced by E1A, and thus allows virus to replicate. In normal cells with p53 
expression, E1b55K-deleted oncolytic Ads do not contain E1B55K to counteract 
E1A-induced p53 accumulation. The p53-mediated cell apoptosis therefore 
prohibits E1b55K-deleted oncolytic Ads to replicate in those cells. However, in 
p53-deficient cancer cells, lack of p53 expression allows oncolytic Ads to replicate 
in the cells without undergoing E1A-induced apoptosis. 
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1.4.2. Cancer selectivity of E1b55K-deleted Ads based on late viral mRNA 
export  
The mechanism that permissive cancer cells provide the late viral RNA export 
functions for E1b55K-deleted Ads to carry out sufficient oncolytic replication was 
proposed by O'Shea et al. (2004) (63) (Fig, 1.3). During the virus replication 
process, the levels of late viral mRNAs raise in cytoplasm for translation whereas 
the accumulation of cellular mRNAs in cytoplasm is blocked (7). E1B55K 
functions in a complex with the viral E4orf6 protein to direct the switch from host to 
viral protein synthesis by promoting the preferential nuclear export and translation 
of the late viral mRNAs to cytoplasm (63-68). Several lines of evidence support 
the hypothesis that the E1B55K/E4orf6 complex is directly involved in the 
selective nuclear export of late viral mRNAs through active nucleocytoplasmic 
shuttling via the exportin CRM1 (7, 64, 69) or through its E3 ubiquitin-protein 
ligase activity (68, 70, 71). However, the molecular mechanism(s) of either 
selective nucleocytoplasmic transport mediated by E1B55K/E4orf6 complex or 
the assembly and activity of the E3 ubiquitin-protein ligase associated with 
E1B55K/E4orf6 complex has not been fully understood (70). Since 
E1b55K-deleted oncolytic Ads lack E1B55K to mediate late viral mRNA export 
from nucleus in primary cells, the viruses fail to efficiently replicate in those normal 
cells (63). Permissive cancer cells, however, have a propensity to support the 
nuclear export of viral late mRNAs in the absence of E1B55K while normal cells 
do not, allowing oncolytic replication of E1b55K-deleted oncolytic Ads to occur.  
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O'Shea et al. (2005) further reported that either restoring viral L4 100K protein 
expression or inducing heat shock responses can partially rescue 
E1b55K-deleted Ad replication in refractory cancer cells (72). In contrast to 
permissive cancer cell lines, for E1b55K-deleted Ad replication, refractory cancer 
cell lines fail to offer preferential nuclear export and translation of viral late mRNAs 
including Ad L4 100K mRNA in the absence of E1B55K (72). Ad L4 100K is known 
to be involved in host protein shutoff and promote preferential nuclear export and 
translation of viral late mRNAs (73-75). As a consequence of the absence of 
E1B55K, lack of L4 100K expression in refractory cancer cells leads to the poor 
oncolytic Ad replication and ectopic expression of L4 100K in refractory cancer 
cells enhanced the expression of late viral proteins. In the same report the authors 
also implied that heat shock proteins overexpressed in various human cancers 
may be the important molecular mechanism for cancer cells to support the 
differential transport of late viral mRNA export between normal and cancer cells. 
The cellular responses to heat shock resemble the late stages of adenovirus 
infection with the inhibited translation of cellular mRNAs and preferential 
translation of heat shock mRNAs. Also it has been shown that the 5'UTR of 
mammalian heat shock protein (Hsp) 70 and late adenoviral mRNAs share 
structural homology, which may contribute to both selective translation and 
nuclear export through a common mechanism (76). Thus induction of heat shock 
responses by physical or pharmacological means could selectively rescue the 
export of late viral mRNAs in refractory cancer cells, rendering them once again 
permissive to E1b55K-deleted Ad replication. 
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However, although expression of L4 100K and inducing heat shock responses 
may participate in determining the cancer selectivity of E1b55K-deleted Ads on 
late viral mRNA export, limited evidence has also shown neither expressing L4 
100K nor inducing heat shock responses could completely restore 
E1b55K-deleted Ad replication to the level of wild-type Ad in a majority of cancer 
cell lines. Since ectopic expression of L4 100K and inducing heat shock 
responses cannot recover wild-type replication capacity in the absence of 
E1B55K, the importance of E1B55K for selective oncolytic Ad replication cannot 
be ignored. The exact mechanics of the interaction of E1B55K, L4 100K, and heat 
shock responses to regulate mammalian and late viral mRNA export which leads 
to cancer selectivity of E1b55K-deleted Ads still required for further studies. 
Additionally, Gonzalez et al. (2006) indicated that it appears overly simplistic to 
generalize that the cancer selectivity of E1b55K-deleted Ads relies on the 
efficiency of viral late mRNA export (77). E1B55K has many more functions than 
regulating the differential export of mRNAs, that are important for Ad replication 
and therefore the outcome of a complex interaction between E1B55K and multiple 







































Figure 1.3. Proposed mechanism that late viral mRNA export determines 
oncolytic selectivity. "N" stands for nucleus and "C" stands for cytoplasm. 
E1B55K/E4orf6 complex mediates the preferential export of late viral mRNAs 
from cell nucleus (N) to cytoplasm (C) to carry out the translation. In normal cells, 
a defect in late viral mRNA export of E1b55K-deleted Ads leads to the failure of 
sufficient virus production. Cancer cells with properties to rescue this export and 
expression of late viral mRNA to allow the oncolytic replication of E1b55K-deleted 
Ads. 
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1.4.3. Cancer selectivity of E1b55K-deleted Ads based on cyclin E or cell 
cycle deregulation 
Studies conducted by Goodrum and Ornelles (1999) showed that the E1B55K 
function in late viral mRNA export may not correlate with the restricted replication 
of E1b55K-deleted Ads in cells under G0/G1 phase (67). Unlike wild-type Ad which 
is able to efficiently produce viral progeny regardless the cell-cycle stages, the 
replication of E1b55K-deleted Ads is restricted in HeLa cells under G0/G1 phase 
but less restricted in cells under S phase. Yet the total amount of cytoplasmic late 
viral mRNA was found to be greater in cells infected during G1 phase than that in 
cells infected during S phase with either the wild-type or E1b55K-deleted Ads. A 
study further suggested that the E1B55K protein has a property to enable the 
virus to overcome the growth restrictions to its replication imposed by the 
cell-cycle stage (78).  
 
Based on our study with large-scale gene arrays, we found that viral E1b products 
affected the expression of numerous genes involved in cell cycle regulation, 
transcription, apoptosis, protein metabolism, stress responses and angiogenesis 
(79). Most importantly, the levels of some key regulators of cell cycle progression, 
including cyclin E and CDC25A, were significantly increased by E1B. 
 
Cyclin E is well-characterized as a critical cell cycle protein to promote G1/S 
phase transition (80, 81) in either cyclin-dependent kinase 2 (CDK2)-dependent 
(82) or CDK2-independent manner (83, 84). Expression of cyclin E is strictly 
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controlled in normal cells while the deregulation of cyclin E is highly related to 
tumorigenesis (85-88). Constitutive overexpression of cyclin E can induce 
chromosome instability and impair normal cell cycle progression (89, 90). Cyclin E 
gene amplification (91), overexpression of cyclin E mRNA or protein levels (87, 
92), decrease of cyclin E turnover (93), together with the presence of more active 
forms of cyclin E (94-96) have been reported in many types of cancers, such as 
breast, gastrointestinal, lung and skin cancers. 
 
We have reported that E1B55K has a novel function to induce cyclin E expression 
which is critical for virus replication (56, 79). The replication of E1b55K-deleted 
oncolytic Ads is restricted in normal cells due to the failure to induce cyclin E. 
Cancer cells, with the cyclin E deregulation, may provide the E1B55K-like factors 
to support cyclin E induction by E1b55K-deleted Ads, leading to sufficient 
oncolytic replication. We thus proposed that cyclin E deregulation in cancer cells 
is a molecular basis of oncolytic selectivity of E1b55K-deleted Ads (Fig. 1.4.). 
Permissive cancer cells may provide E1B55K-like factors to relax cyclin E 
regulation and allow E1b55K-deleted Ads to induce cyclin E expression similarly 
to wild-type Ad in cancer cells, but not normal cells, leading to preferential 
oncolytic replication. Ad-induced cyclin E subsequently activates CDK2 which 
inhibits the transcriptional suppressor pRb to generate a cellular environment for 





































Figure 1.4. Proposed mechanism that cyclin E deregulation in cancer cells 
is the molecular basis of oncolytic selectivity. In Ad-infected normal cells, Ad 
E1B55K functions to enhance cyclin E expression for virus replication. Without 
E1b55K to induce cyclin E, E1b55K-deleted oncolytic Ads cannot replicate in 
normal cells. Permissive cancer cells provide E1B55K-like factors to relax cyclin E 
regulation and allow E1b55K-deleted Ads to induce cyclin E expression; leading 
to preferential oncolytic replication. 
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1.5. Scope of the dissertation 
Ad dl1520 was originally created in United States, but the development for clinical 
applications was aborted. However, this vector with a slight modification became 
the first approved oncolyitc virus product (H101) on the China market and now 
achieves some measure of success in cancer treatment (18). There is an urgent 
need for us to improve current strategies to design viral vectors, and further 
improve the insights into the field of oncolytic virotherapy. The work contained 
within this dissertation has been proposed based on the hypothesis that cyclin E 
deregulation in cancer cells is the molecular basis of oncolytic selectivity of 
E1b55K-deleted Ads. We advanced the previous findings to further develop the 
mechanism model to demonstrate the role of cyclin E in the selective replication of 
E1b55K-deleted oncolytic Ads. The virtual application was then derived from the 
knowledge of this mechanism model. Our laboratory then constructed a novel 
tumor-specific oncolytic Ad-cycE with cyclin E promoter to drive E1A expression. 
The oncolytic efficacy of this novel oncolytic Ad vector has been evaluated in vitro 
and in vivo. Additional work has been completed exploring the impact of a 
combination treatment with Ad-cycE and rapamycin which induces rapamycin in 
lung cancer. Ultimately, by uncovering the selective replication mechanism of 
oncolytic Ad and its further application, we hope to overcome the current 
limitations; leading to advancement for the field of oncolytic virotherapy. 
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CHAPTER II 
MOLECULAR BASIS FOR VIRAL SELECTIVE REPLICATION IN CANCER 
CELLS: ACTIVATION OF CDK2 BY ADENOVIRUS-INDUCED CYCLIN E 
 
2.1. Introduction 
Human adenoviruses (Ads) are double-stranded linear DNA viruses that are able 
to infect and replicate in a wide variety of cell types in vitro and in vivo, including 
post-mitotic cells. After infection, viral early proteins interact with cellular factors to 
create favorable environments for viral replication (37). The Ad E1 region contains 
two sets of genes, E1a and E1b, that are dedicated to cell cycle control, apoptotic 
inhibition, and cellular and viral gene regulation (97). Ads with E1 modifications 
that preferentially replicate in cancer cells have been used for cancer gene 
therapy (15-17). 
The viral E1a gene is expressed immediately after infection. The primary role of 
E1a gene products is to regulate expression of multiple cellular and viral genes 
(37). Instead of directly binding to specific DNA sequences in transcriptional 
regulation elements, E1A proteins interact with several key regulators of cell 
proliferation (98, 99). The well-known cellular factors to which E1A proteins bind 
are products of the retinoblastoma (Rb) gene and its structurally related genes, 
p107 and p130 (100, 101). By sequestering the retinoblastoma protein (pRb), E1A 
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activates transcriptional regulator E2F proteins. Studies have suggested that the 
pRb/E2F complex actively represses transcription from target genes and 
mediates G1 arrest triggered by p19 (ARF), p53, p16INK4a, TGF beta, or cell 
contact (102-104). Recently Pelka et al. (2011) indicated that E1A can directly 
bind to E2F/DP complexes by interacting with DP-1, resulting in the activation of 
E2F-responsive gene expression independently of binding to pRb (105). Several 
groups have shown that expression of E1a gene triggers the accumulation of p53 
protein and p53-dependent apoptosis (40, 106) either by activating p53 
transcription or preventing p53 from being degraded by the proteasome (40, 41, 
43, 106).  
Ad E1B55K has been shown in some studies to counteract the E1A-induced 
stabilization of p53 (106, 107). E1B55K protein may inhibit the functions of p53 
through at least three distinct mechanisms. E1B55K reportedly binds the amino 
terminus of p53 (44), and this binding may repress p53 transcriptional activation, 
as suggested in transcription assays (45) and transient transfection studies (108). 
E1B55K may also interfere with p53 function by cooperating with viral E4orf6 
protein to cause proteolytic degradation of p53 protein (46-48). A recent study has 
shown that E1B55K alone functions as an E3 SUMO1-p53 ligase that interacts 
with promyelocytic leukemia nuclear bodies to inactivate p53 and stimulate its 
nuclear export (49). Thereby, E1B55K blocks the expression of p53-regulated 
genes and, consequently, counteracts the p53-dependent apoptosis induced by 
E1A; allowing efficient viral replication (44, 45).  
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Ad dl1520 (ONYX-015) contains an 827-bp deletion and a point mutation 
generating a premature stop codon in the E1B55K coding sequence, preventing 
expression from the gene (15). It was originally proposed that the E1b55K-deleted 
Ads could replicate only in p53-deficient tumor cells, as the E1B55K-mediated 
degradation of p53 protein was not required in those cancer cells (16, 109). 
E1b55K-deleted oncolytic Ads have been tested in human clinical trials and are 
being marketed for cancer treatment in China after approved by China's State 
Food and Drug Administration (SFDA) (18). However, the original hypothesis was 
challenged by several studies showing that E1b55K-deleted Ads are able to 
replicate in cells regardless of their p53 status (52-55). Further studies have 
shown that the accumulation of p53 protein, after infection with Ads carrying 
mutated E1b55K genes that are unable to repress p53, can neither efficiently 
induce apoptosis nor transcriptionally activate expression of p53-responsive 
genes in Ad-infected cells (62, 63). Thus, these results suggest that blocking of 
p53 activity by E1B55K protein is unlikely to be the major requirement for viral 
replication. The mechanism(s) of E1b55K-deleted viral replication in cancer cells 
is still not established, even though the vectors have already been applied in the 
clinic for human cancer treatment (18).   
Previously, we have shown that Ad E1B55K is involved in the induction of cell 
cycle-related genes, including cyclin E and CDC25A (79). Ad E1B55K mediates 
the large form of cyclin E protein (cyclin EL) induction in Ad-infected cells (56). 
Cyclin E and the large form cyclin EL are generated from the alternative splicing. 
The translation of cyclin EL is initiated at an ATG codon located in exon 2 and 
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cyclin E is from the ATG codon in exon 3 (80). The E1B55K function is required for 
cyclin EL induction in normal cells, but is not required in cancer cells with 
deregulated cyclin E. Failing to efficiently induce cyclin EL expression in the 
normal cells, replication of E1b55K-deleted oncolytic Ads is restricted. However, 
E1b55K-deleted oncolytic Ads can efficiently induce cyclin EL in cancer cells and 
carry out sufficient oncolytic replication. We proposed that cyclin E deregulation in 
cancer cells may be an important molecular basis for the selective oncolytic 
replication of E1b55K-deleted Ads (56). 
Cyclin E regulates cell cycle progression, DNA replication (110, 111), and 
centrosome duplication (112, 113). Expression of cyclin E is strictly controlled in 
normal cells. The level of cyclin E rises at late G1 phase, peaks at the G1/S phase 
to promote the S-phase entry, and decreases thereafter (80, 81). Deregulation of 
cyclin E is frequently detected in many types of cancers, as cyclin E gene 
amplification (91), overexpression of cyclin E mRNA or protein levels (87, 92), 
decrease of cyclin E turnover (93), and the presence of more active forms of 
cyclin E (94-96). Constitutive overexpression of cyclin E was shown to induce 
chromosome instability and impair normal cell cycle progression (89, 90). The 
hypothesis that abnormal cyclin E expression can trigger tumors has also been 
supported by transgenic animal studies (86, 114, 115). 
 
One function of cyclin E is to bind and activate cyclin-dependent kinase 2 (CDK2) 
(82). The cyclin E/CDK2 complex then phosphorylates substrates such as pRb 
and leads to transcriptional activation of downstream genes. Studies also indicate 
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that cyclin E has CDK2-independent functions (83, 84). In vivo animal studies 
indicate variance between the phenotypes of cyclin E null (cyclin E1-/- E2-/-) mice 
and CDK2 null (CDK2-/-) mice. Mice lacking CDK2 are viable, with normal 
development except defective germ cell development (116, 117); yet knockout of 
cyclin E1 and E2 genes in mice causes embryonic lethality owing to the deficiency 
in endoreplication of trophoblast giant cells and megakaryocytes (118). 
Matsumoto et al. (2004) identified a centrosomal localization signal (CLS) domain 
in cyclin E (119). This CLS domain allows cyclin E to target the centrosome and 
promote S phase entry in a CDK2-independent manner. Additionally, Geng et al. 
(2007) showed that a cyclin E kinase-deficient mutant (KD-E) is able to partially 
restore minichromosome maintenance protein (MCM) loading and S phase entry 
in cyclin E null cells (83). Thus, cyclin E has CDK2-dependent and independent 
functions in S phase entry and DNA replication. An important question is whether 
Ad-induced cyclin E may activate CDK2 and whether the cyclin E-CDK2 
interaction may play a crucial role in Ad replication. This question is especially 
important in the development of oncolytic virotherapy strategies.  
 
We report here that Ad-induced cyclin E binds with and activates CDK2 that 
targets transcription repressor pRb, which in turn can regulate expression of 
cellular and viral genes. The results suggest that the interaction between the 
Ad-induced cyclin E and CDK2 is to generate a suitable environment for Ad 
productive replication.
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2.2. Materials and Methods 
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), human lung 
fibroblast WI-38 (ATCC no. CCL-75), and human lung cancer A549 (ATCC no. 
CCL-185) cell lines were purchased from the American Type Culture Collection 
(Rockville, MD). WI-38 cells were cultured in minimal essential medium (MEM) 
Alpha GlutaMAX with 0.1 mM non-essential amino acids and 1.0 mM sodium 
pyruvate. HEK 293 and A549 cells were cultured in minimal essential medium 
Alpha. All media were supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at 
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD).  
 
Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was 
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1 
deletion carrying a green fluorescent protein (GFP), was used as a 
replication-defective control. Adhz63, an oncolytic Ad vector with the deletion of 
E1b55K region, was constructed by our laboratory (38). 
 
Viral infection and titration. Cells were seeded into 6-well plates at a density of 
2.5 x 105 (cells/well) and cultured under the indicated conditions. Subsequently, 
cells were mock-infected or infected with AdGFP, Adwt, or Adhz63 at a multiplicity 
of infection (MOI) of 5. Cytopathic effect (CPE) was observed at designed time 
points and photographed with an inverted microscope (Olympus CKX41). Total 
infected cells and culture supernatants were collected at 48 hr postinfection (p.i.) 
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and lysed to release virus particles with three cycles of freezing and thawing. The 
viral titers were determined by the infective unit method as described previously 
(120, 121). Briefly, HEK 293 cells were seeded in 96-well plates at a density of 103 
(cells/well) and then infected with 5-fold serially diluted viruses. CPE was 
recorded and scored after incubation for 7 days. The reduction percentage in virus 
titer is calculated by the formula, reduction % = [(titer of control group – titer of 
experimental group) / titer of control group] x 100%. 
 
Viral DNA synthesis assay. After viral infection, cells were collected at different 
time points. The viral DNA synthesis was determined with Southern blot; 1 µg of 
isolated genomic DNA was digested with the restriction enzyme PstI and analyzed 
with 1% agarose gel, which was subsequently transblotted to a Hybond-N+ 
membrane (YA3609; Amersham Pharmacia Biotech, Arlington Heights, IL). The 
probe was prepared by digesting 0.5 µg pBHGE3 (122) with PstI and labeled by 
following the protocol of Amersham AlkPhos Direct Labeling and Detection 
Systems (RPN 3690; GE Healthcare, Piscataway, NJ). The blot was 
prehybridized for 3 hrs at 63°C. The hybridization and stringency washes were 
performed at 55°C and followed by the chemiluminescent detection according to 
the manufacturer’s protocol. 
 
Western blot analysis. Infected cells were harvested at indicated time points and 
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium 
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vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as 
described previously (123). Briefly, 80 µg of cell lysates were electrophoresed 
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P 
Membrane (Millipore, Billerica, MA). The primary antibodies used in this study 
were rabbit anti-cyclin E (M-20), CDK4 (C-22), mouse anti-cyclin D1 (DCS-6), 
PCNA (PC10), p21 (F-5), pRb (IF8) (Santa Cruz Biotechnology, Santa Cruz, CA), 
mouse anti-CDK2, p27 (BD Biosciences, San Jose, CA), pCDK2 T160 (Cell 
signaling, Danvers, MA), rabbit anti-phosphorylated pRb (phospho-pRb) S612, 
and actin (Sigma, St. Louis, MO), anti-phospho-pRb S795 (New England Biolabs, 
Beverly, MA), and anti-phospho-pRb T821 (Invitrogen, Carlsbad, CA). Actin was 
used as an internal control. The membranes were then incubated with anti-mouse 
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific 
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection 
was performed with ECL reagents according to the supplier’s recommendations 
(GE Healthcare). The scanned band intensity was quantitated by Gel-pro 
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) according to the 
manufacturer’s tutorial. Densitometric value for each band was expressed as 
integrated optical density (I.O.D.) and the results were normalized with actin. The 
final values represent the means of relative percentage change, from at least 
three independent experiments, compared with the mock group ± S.D.. Statistical 




Immunoprecipitation. A549 cells were seeded in 150 mm dishes at a cell density 
of 5 x106 (cells/dish) and then mock-infected or infected with AdGFP, Adwt, or 
Adhz63 at an MOI of 5. At 48 hr p.i., cells were collected and lysed with CDK2 
lysis buffer according to the method described in previous publications (56, 124). 
Cell lysates (500 µg) were immunoprecipitated with cyclin E (HE111), the mouse 
monoclonal antibody (Santa Cruz), or anti-CDK2 antibody (BD Transduction 
Laboratories) at 4°C for 4 hr, followed by adding protein A Sepharose CL-4B 
(82506; Sigma) and incubating overnight. Immunocomplexes were analyzed by 
Western blot with anti-cyclin E and CDK2 antibodies.  
 
Small interfering RNA (siRNA) transfection. The siRNA oligonucleotides were 
synthesized by Eurogentec (Fremont, CA). Three different siRNA duplexes were 
designed to target CDK2 on nucleotides 399 to 419 (#1), 619 to 639 (#2), and 691 
to 711 (#3) according to Genbank accession NM001798.2 (National Center for 
Biotechnology Information GenBank). A negative control siRNA duplex containing 
two strands of 19 complementary RNA bases with 3’dTdT overhangs was 
obtained from Eurogentec (SR-CL000-005). Cells were seeded into a 6-well plate 
at a density of 105 (cells/well) and then transfected with 200 nM CDK2 siRNA 
duplexes or a non-specific control siRNA duplex with Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Cells were 
harvested at 48 hr after transfection. Eighty µg of cell lysates were analyzed by 
Western blot with CDK2, pCDK2 T160, pRb, phosphorylated pRb (p-pRb), cyclin 
E, capsid proteins, and actin antibodies. 
 29 
2.3. Results 
Cyclin E/CDK2 complex formed in cells infected with adenoviruses. We have 
previously established the link between cyclin E and replication of adenoviruses 
(56, 79). The data shown in Figure 2.1 recapitulate that Ad E1B55K participates in 
the induction of the large form of cyclin E protein (cyclin EL), which contributes to 
the efficient viral replication. Cyclin E and cyclin EL are generated from alternative 
splicing with different start ATG codons in exons 2 and 3 (80). The N terminus of 
virus-induced cyclin EL is 15 amino acids longer than that of cyclin E protein. 
Cyclin E protein is constitutively expressed in A549 human lung cancer cells (56). 
Wild-type Ad5 (Adwt), with the intact E1b55K region, induced significant cyclin EL 
expression in both of WI-38 human lung fibroblast cells and A549 human lung 
cancer cells (Fig. 2.1A, lanes 2 and 5), and caused efficient cytopathic effect (CPE) 
(Fig. 2.1B, panels b and e). Ad vector Adhz63 with E1b55K-deletion (38) also 
induced significant cyclin EL in A549 cells (Fig. 2.1A, lane 6) and caused efficient 
CPE of the cells (Fig. 2.1B, panel c). However, the vector failed to induce cyclin 
EL overexpression in WI-38 cells (Fig. 2.1A, lane 3) and their CPE (Fig. 2.1B, 
panel f). To compare the replication of Adwt and Adhz63 in A549 and WI-38 cells, 
the titers of these two viruses were determined. The Adhz63 replication was 
strongly repressed in WI-38 cells, showing only 10% of relative replication in 
comparison with Adwt (Fig. 2.1C). When we compared Adhz63 replication with 
that of Adwt in A549 cells, consistent with the CPE results, 80% of relative 
replication of Adhz63 was observed. Thus, Adhz63 replication is more repressed 
in WI-38 cells than in A549 cells. The result is consistent with our previous 
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observation that cyclin EL induction in cancer cells is connected with the selective 







Figure 2.1. Virus replication is correlated with cyclin E overexpression. 
WI-38 or A549 cells were infected with AdGFP, Adwt or Adhz63 at an MOI of 5. (A) 
Cells were collected at 48 hr and then analyzed by Western blot. Cell lysates were 
immunoblotted for cyclin E and actin. Actin was used as a loading control. (B) 
CPE was photographed at 72 hr post infection (p.i.). All microscopy was originally 
at a magnification of x100. (C) Viral titers were determined at 72 hr p.i. with the 
infection unit method. The value indicates the mean of three independent 
experiments, shown as the mean change percentage relative to Adwt control 
group ± S.D. * P<0.05 compared with the Adwt group, Student’s t-test.
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Cyclin E can promote the S phase entry and participate in DNA replication via 
CDK2-dependent (82) and CDK2-independent pathways (119). To study whether 
cyclin E function in Ad replication is CDK2 dependent or independent, we first 
sought to investigate the physical contact between CDK2 and cyclin EL in cells 
affected by Ads. Lung cancer A549 cells were mock-infected or infected with 
AdGFP, Adwt, or Adhz63. To understand how E1b-deleted Ads selectively 
replicate in cancer cells, we focused on A549 lung cancer cells in which both Adwt 
and the E1b-deleted Adhz63 can efficiently induce cyclin EL and replicate. At 
48 hr post-infection (p.i.), cells were collected and lysed. We first used anti-cyclin 
E antibody to immunoprecipitate cyclin E protein and analyzed the 
immunocomplexes with Western blot. The data show that cyclin E protein 
precipitated from cells mock-treated or treated with replication-defective AdGFP 
(negative controls) did not exhibit significant association with CDK2 protein (Fig. 
2.2A, lanes 1 and 2). However, immunocomplexes from Adwt- and 
Adhz63-infected A549 cells contained both cyclin E and cyclin EL with an increase 
of CDK2 binding (Fig. 2.2A, lanes 3 and 4). To verify this cyclin E/CDK2 bonding, 
we also used anti-CDK2 antibody to pull down the protein complex and then 
examined the level of cyclin E proteins in the cyclin E-CDK2 complex. The 
immunoprecipitated CDK2 protein was increased in Adwt and Adhz63-infected 
cells with a concomitant precipitation of cyclin EL (Fig. 2.2B, lanes 3 and 4), 
especially for Adwt-infected cells (lane 3). The results show that 
replication-competent Adwt and Adhz63 induce cyclin EL expression and increase 
the formation of cyclin EL/CDK2 complex in A549 cancer cells, indicating that the 
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Figure 2.2. Cyclin E/CDK2 complex induced by viral infection in A549 cells. 
(A) A549 cell lysates were immunoprecipitated with anti-cyclin E antibody (1:50 
dilution). Immunocomplexes were analyzed by Western blot with cyclin E and 
CDK2 antibodies. (B) The cell lysates were immunoprecipitated with anti-CDK2 
antibody and immunoblotted for CDK2, cyclin E and cyclin EL.
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Adenovirus-induced cyclin EL increases CDK2 phosphorylation. CDK2 is 
activated by the phosphorylation at the T160 site and this phosphorylation 
increases its electrophoretic mobility, resulting in faster-migrating bands (125). We 
investigated whether cyclin EL induction and the increased interaction between 
cyclin EL and CDK2 in A549 cells after Adwt and Adhz63 infection may promote 
CDK2 phosphorylation at the specific T160 site. Analysis of the cell lysates with 
Western blot demonstrated that the cyclin EL induction led to an increase of the 
faster-migrating CDK2, consistent with phosphorylated-CDK2 protein (pCDK2) 
T160 (the active form of CDK2), especially at 48 hr p.i. (Fig. 2.3A, lanes 7 and 8). 
We verified the faster-migrating form of CDK2 with phospho-CDK2 (T160) 
antibody (#2561, Cell signaling). Densitometric analysis of these bands 
demonstrated that Adwt infection caused a 1.3 to 2.7-fold increase (P = 0.03) in 
the level of pCDK2 T160 and Adhz63 infection caused a 1.5 to 1.9-fold increase 
(P = 0.0026) compared with the mock-control group at 48 hr p.i. (Fig. 2.3B, lanes 
3 and 4). The result in Figure 2.3B is consistent with that in Figure 2.3A (lanes 7 
and 8).  
 
In addition to cyclin E, cyclin D is also involved in the transition of the G1-S phase. 
Thus, we also examined the level of cyclin D. Interestingly, the level of cyclin D 
was decreased after viral infection. Densitometric analysis of the bands 
demonstrated that Adwt and Adhz63 infection at 24 hr decreased cyclin D protein 
to the levels of 11% (P = 0.0000025) and 71% (P = 0.001) of the mock infection, 
respectively (Fig. 2.3C, lanes 3 and 4). The levels of cyclin D in cells infected with 
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Adwt or Adhz63 were further decreased at 48 hr to 3% (P = 0.00000043) and 8% 
(P = 0.00002), respectively (Fig. 2.3C, lanes 7 and 8). Meanwhile, the level of 
CDK4 and the proliferating cell nuclear antigen (PCNA) did not significantly 
change in any of the groups. CDK4 is regulated and activated by cyclin D to 
process the G1-S transition (126, 127); PCNA, known to regulate DNA replication 
and DNA repair, is associated with multiple cyclin/CDK complexes in the cell-cycle 
progression (128, 129). The results show that Ads decreased cyclin D production 
and did not affect the levels of CDK4. Thus, Ad infection specifically induced 
cyclin EL that activated CDK2 via phosphorylation at its T160 site, suggesting a 





Figure 2.3. Effects of viral replication on cellular proteins related to G1/S 
phase. A549 cells were mock infected or infected with AdGFP, Adwt, or Adhz63 at 
an MOI of 5. Cells were collected at 24 hr or 48 hr p.i. and then analyzed by 
Western blot. Cell lysates were immunoblotted for (A) cyclin E and CDK2; (B) 
pCDK2 T160; and (C) cyclin D, CDK4 and PCNA. Actin was used as a loading 
control. The scanned band intensity was quantitated and the values represent the 
means of the relative change percentages compared with the mock group ± S.D. 
from three independent triplicate experiments. * P<0.05 compared with the 
mock-control group, Student’s t-test. 
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Adenoviruses increase pRb phosphorylation. Cyclin E-activated 
phosphorylated CDK2 (pCDK2) is known to control the G1-S transition by 
phosphorylation of the downstream substrates. Considering that pRb is one of the 
well-known targets for pCDK2, we examined whether the increase of activated 
pCDK2 alters the phosphorylation of pRb at S612, which is a CDK2-preferred 
phosphorylation residue (130, 131). We found that the level of phospho-pRb S612 
was increased to 314% (P = 0.016) and 240% (P = 0.03) in cells infected with 
Adwt and Adhz63, respectively, even though the protein level of 
unphosphorylated pRb is decreased slightly (Fig. 2.4A, lanes 3 and 4). We could 
not detect any significant changes of p-pRb T821, another CDK2-preferred 
phosphorylation residue (130, 132), and the CDK4-preferred p-pRb S795 (133) 
(Fig. 2.4A). The results suggest the selection of the S612 site in pRb by 
Ad-activated CDK2 for protein phosphorylation. 
 
Adenoviruses repress CDK inhibitors. We also observed that the protein levels 
of both p21 and p27 are decreased in A549 cells infected with Adwt and Adhz63, 
especially for p21 (Fig 2.4B). p21 and p27 are the well-known CDK inhibitors, 
which negatively regulate the activity of cyclin E/CDK2 complexes to prevent the 
cell-cycle progression (134). Densitometric analysis of these bands demonstrated 
that the level of p21 protein decreased to the levels of 8% (P = 0.0000002) and 
44% (P = 0.00066) of the mock control in A549 cells after infection with Adwt and 
Adhz63 at 24 hr, respectively (Fig. 2.4B, lanes 3 and 4). The p21 level was further 
repressed in A549 cells at 48 hr after infection with Adwt (2%, P = 0.00000034) 
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and Adhz63 (6%, P = 0.0000007) (Fig. 2.4B, lanes 7 and 8). Ad infection also 
decreased p27 protein levels to 36% (Adwt, P = 0.0015) and 49% (Adhz63, P = 
0.00043) at 24 hr; 16% (Adwt, P = 0.00012) and 37% (Adhz63, P = 0.0092) at 48 
hr in A549 cells (Fig. 2.4B). The results suggested that Ads activate the CDK2 by 













Figure 2.4. Effects of viral replication on pRb and CDK inhibitors. A549 cells 
were mock-infected or infected with AdGFP, Adwt, or Adhz63 and collected at 24 
hr or 48 hr p.i., followed by Western blot analysis. Cell lysates were 
immunoblotted for (A) pRb, phospho-pRb (p-pRb) at S612, T821 and S795 or (B) 
p21 and p27. Actin was used as a loading control. * P<0.05 compared with the 
mock-control group, Student’s t-test.
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Interruption of cyclin EL and CDK2 interaction reduces adenoviral 
replication. To further investigate the role of CDK2 in viral replication, we used 
the CDK2 chemical inhibitor roscovitine (Ros; CYC202) to interrupt cyclin EL and 
CDK2 interaction. Ros is a purine derivative that inhibits the activity of CDK2 by 
binding to its active site (135). Ros reduces phosphorylation on CDK2 (136) and 
blocks the androstenedione-induced increase of active phosphorylated CDK2 
(137). If activation of CDK2 is required for viral replication, blocking CDK2 activity 
should reduce it. Figure 2.5A, representing one of the four repeated experiments, 
shows that with increased Ros, CPE caused by Adwt and Adhz63 infection was 
partially inhibited. Figure 2.5B shows that treatment with 5 µM of Ros led to a 50% 
reduction in Adwt titer (P = 0.0002) and 71% reduction in Adhz63 titer (P = 0.034) 
when compared with the vehicle-control group treated with dimethyl sulfoxide 
(DMSO, defined as 0 µM Ros). Treatment with 10 µM Ros led to more decreases 
of viral titers: 81% reduction in Adwt (P = 0.00001) and 87% reduction in Adhz63 
(P = 0.012). The repressed viral yields are consistent with the CPE phenomenon 






















Figure 2.5. Effects of roscovitine on CPE and viral production. (A) Cells were 
treated with 0 µM (vehicle-control group treated with DMSO), 5 µM, or 10 µM 
roscovitine, and mock-infected or infected with AdGFP, Adwt or Adhz63 at an MOI 
of 5. All microscopy is originally at a magnification of x100 taken at 48 hr p.i. (B) 
Viral titers were determined at 48 hr p.i. with the infection unit method. The values 
represent the means ± S.D. of independent quadruplicate. * P<0.05 compared 
with the 0 µM roscovitine, Student’s t-test.
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We then examined the levels of viral DNA and proteins produced in cells affected 
by Ros treatment. The viral DNA synthesis was determined by Southern blot 
probed with the Ad genome. The linear Adwt DNA is 36 Kb with total 28 PstI 
restriction sites. The largest fragment is 4333 bp and the smallest fragment is only 
12 bp. The sizes of the representative DNA fragments were marked on Figure 2.6. 
The viral DNA synthesis of Adwt and Adhz63 at 24 hr p.i. was strongly inhibited in 
the presence of 10 µM Ros (Fig. 2.6A, lanes 6 and 12). Consistently, the viral 
capsid proteins were significantly inhibited in the presence of 10 µM Ros (Fig. 
2.6B, lanes 4 and 6). Inhibition of CDK2 activity with Ros reduced the 
phosphorylation of pRb at the S612 site in AdGFP, Adwt and Adhz63-treated cells 
(Fig. 2.6C). Interestingly, Ros treatment markedly repressed the induction of 
cyclin EL protein caused by Adwt and Adhz63 infection (Fig. 2.6C, lanes 4 and 6). 
To sum up, these data show that inhibition of CDK2 with Ros repressed pRb 































Figure. 2.6. Effects of Ros on viral DNA synthesis, viral capsid proteins, 
virus-induced cyclin E and phospho-pRb S612. (A) A549 cells were collected 
at 0 hr and 24 hr p.i. Viral DNA synthesis was determined by Southern blot. At 24 
hr p.i., cells were harvested and cell lysates were immunoblotted for (B) 
adenovirus type 5 capsid proteins, (C) cyclin EL, p-pRb S612, and actin. Actin 
was used as a loading control. * P<0.05 compared with the 0 µM 
roscovitine-treated group, Student’s t-test. 
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siRNA inhibiting CDK2 represses adenoviral replication by preventing pRb 
phosphorylation. Since the chemical inhibitor Ros may also influence other CDK 
and kinases (138), we also applied RNA interference to specifically silence CDK2 
expression. We tested three different pairs of siRNA duplexes targeting CDK2 on 
the coding region and showed that all CDK2 siRNAs dramatically inhibited CDK2 
expression without the detectable influence on the non-targeted CDK4 in A549 
cells (Fig. 2.7A). To evaluate the effects of CDK2 on the cellular protein production 
in response to viral infection, A549 cells were infected with Adwt or Adhz63 after 
treatment with CDK2 siRNA duplex or a non-specific control siRNA for 48 hours. 
Figure 2.7B, representing one of the three repeated experiments, shows that 
blockage of CDK2 expression with siRNA partially inhibited Adwt and 
Adhz63-induced CPE. Inhibition of CDK2 expression with siRNA resulted in the 
decreases of Adwt titer from 1.4 X 109 (control siRNA) to 2.8 X 108 (specific siRNA) 
and Adhz63 titer from 1.2 X 108 to 4.2 X 107 (Fig. 2.7C). The effect of CDK2 
siRNA on viral replication is statistically significant; the titers decreased about 5 
fold for Adwt (P = 0.0005) and 3 fold for Adhz63 (P = 0.03).  
 
We also evaluated the effects of CDK2 on the cellular protein production in 
response to viral infection. As we expected, the CDK2 siRNA specifically 
repressed the production of CDK2 protein and decreased pCDK2 T160 in Adwt 
and Adhz63-infected cells (Fig. 2.7D, lanes 2 and 4). Repression of CDK2 also 
resulted in reduced CDK2-specific phosphorylation on pRb, but did not decrease 
pRb protein levels. In addition, we observed that treatment with CDK2 siRNA 
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repressed specifically Ad-induced cyclin EL, but not cyclin E (Fig. 2.7D, lanes 2 
and 4). This agreed our findings with Ros (Fig. 2.6C) showing that specifically 
inhibiting CDK2 with siRNA significantly repressed viral production, which 
correlated with the decreased CDK2 activation and phosphorylation on pRb in 





























Figure 2.7. Effects of CDK2-specific siRNA on Ad replication in A549 human 
lung cancer cells. (A) A549 cells were transfected with 200 nM siRNA duplexes 
targeting different coding regions of CDK2. “Mix” represents the mixture of three 
pairs of siRNA duplexes (#1, #2 and #3). Cells were harvested at 48 hr after 
transfection. Cell lysates were immunoblotted for CDK2, CDK4, and actin. (B) At 
48 hr after transfection with CDK2 siRNA duplex or a duplex of non-specific 
control siRNA, cells were infected with Adwt or Adhz63 at an MOI of 5. CPE was 
photographed at 48 hr p.i. All microscopy is originally at a magnification of x100. 
(C) The viral titers were determined at 48 hr p.i. with the infection unit method. 
The values are means ± S.D. of independent triplicate. * P<0.05 compared with 
the control group, Student’s t-test. (D) The infected cells were harvested at 24 hr 
after infection. Cell lysates were immunoblotted for CDK2, pCDK2 T160, pRb, 
p-pRb S612, cyclin E, cyclin EL, and actin. Actin was used as a loading control. 
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siRNA inhibiting CDK2 repressed wild-type adenovirus replication in normal 
cells. Considering that the control of G1 exit is generally abnormal in cancer cells, 
we verified the role of CDK2 in Ad replication in WI-38 human diploid cell line that 
was derived from the normal embryonic lung tissue (139). As Adhz63 poorly 
induces cyclin EL and replicates in WI-38 cells (Fig. 2.1), we therefore 
investigated Adwt replication in WI-38 cells with the non-replication AdGFP as a 
negative control. WI-38 cells were infected with AdGFP or Adwt after transfected 
with CDK2 siRNA duplex or a non-specific control siRNA for 48 hr. Figure 2.8A, 
representing one of the three repeated experiments at 72 hr p.i., shows that 
blockage of CDK2 expression with siRNA partially inhibited Adwt-induced CPE as 
we observed with Adwt-infected A549 cells. Inhibition of CDK2 expression with 
the specific siRNA caused a significant decrease of Adwt titer from 2.2 X 108 to 
1.8 X 107 (P = 0.03, Fig. 2.8B). In addition, CDK2 repression also dramatically 
inhibited the viral DNA synthesis (Fig. 2.8C, lane 4) and capsid protein production 
(Fig. 2.8D, lane 4).  
 
The level of cellular proteins in response to viral infection altered by CDK2 
inhibition was also examined in WI-38 cells. For cells treated with the non-specific 
control siRNA, we were unable to detect pCDK2 T160 and cyclin E in WI-38 cells 
treated with AdGFP (Fig. 2.8E); this is related to the strict control of cyclin E 
expression in WI-38 cells. Adwt infection significantly increased CDK2, pCDK2 
T160, and cyclin EL (Fig. 2.8E, comparing lanes 1 and 3). Inhibition of CDK2 by 
the siRNA repressed the pCDK2 T160, phospho-pRb S612, and cyclin EL 
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induced by Adwt infection (Fig. 2.8E, comparing lane 1 with 2 and lane 3 with 4). 
Adwt infection and siRNA treatment did not show significant effects on pRb (Fig. 
2.8E). Taken together, the results suggest that CDK2 activated by Ad-induced 










Figure 2.8. Effects of CDK2-specific siRNA on Ad replication in WI-38 human 
lung fibroblast cells. WI-38 cells were transfected with CDK2 siRNA duplex or a 
duplex of non-specific control siRNA. At 48 hr after transfection cells were infected 
with AdGFP, Adwt, or Adhz63 at an MOI of 5. (A) CPE was photographed at 72 hr 
p.i. All microscopy was originally at a magnification of x100. (B) The viral titers 
were determined at 72 hr p.i. with the infection unit method. The values are 
means ± S.D. of independent triplicate. * P<0.05 compared with the control group, 
Student’s t-test. (C) Cells were collected at 48 hr p.i. and viral DNA synthesis was 
determined by Southern blot. Cell lysates were immunoblotted (D) for adenovirus 
type 5 capsid proteins and for (E) CDK2, pCDK2 T160, pRb, p-pRb S612 and 





By using multiple cell lines (A549, WI-38, HCT116, RKO, HepG2, Hep3B, Saos2, 
HeLa, MDA-MB-231, and HT29), we previously have shown that induction of 
cyclin EL is required for Ad replication and correlated with oncolytic selectivity of 
E1B55K-deleted Ad (56, 79). In this report, we extended the study and focused on 
cyclin E and CDK2 interaction in human lung cells that are natural host cells for 
human adenoviruses; we demonstrated that CDK2 activation by cyclin EL is a 
critical molecular step in Ad replication. Three lines of evidence support the 
importance of activation of CDK2 by cyclin EL in Ad replication. First, Ad-induced 
cyclin EL directly interacted with CDK2 and formed cyclin EL/CDK2 complex, 
leading to specifically increased phosphorylation of CDK2 and pRb (CDK2 at 
T160 and pRb at S612). Second, the CDK2 chemical inhibitor roscovitine 
decreased viral replication. Finally, the siRNA specifically inhibiting CDK2 
repressed the viral replication with the decrease in pRb phosphorylation. These 
three lines of evidence support the hypothesis that Ad-induced cyclin EL activates 
CDK2, which targets the transcriptional suppressor pRb, controlling cellular and 




























Figure 2.9. Proposed mechanism of cyclin E function in Ad replication. In 
Ad-infected cells, Ad E1B55K has a function to enhance cyclin E expression. This 
E1B55K function is not required for virus replication in cancer cells, which may 
provide E1B55K-like factors to relax cyclin E regulation and promote cell cycle 
progression. Cyclin E binds to and activates CDK2. Subsequently, the active 
pCDK2 phosphorylates the transcriptional repressor pRb, leading to the 
expression of multiple genes, including cyclin E, to provide a suitable cellular 
environment for viral replication. 
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Cyclin E and the large form cyclin EL are generated from alternative splicing. The 
translation of cyclin EL is initiated at an ATG codon located in exon 2 and cyclin E 
is from the ATG codon in exon 3 (80). It has been reported that cyclin EL is found 
predominantly in breast tumor cells with the abundant lower-molecular-weight 
(LMW) isoforms (140, 141). We previously constructed a plasmid, pTet-cycE, 
containing cyclin E cDNA that produces these two forms of cyclin E proteins (56). 
With this approach we clarified that the A549 cell line constitutively expresses the 
regular cyclin E protein (cyclin E), and Ad infection mainly induces the expression 
of large form cyclin E protein (cyclin EL) (56). It is still unclear why Ad infection 
mainly induces cyclin EL. Considering that cyclin E has CDK2-dependent (82) 
and independent functions that are related to participation in DNA replication 
licensing (83) and oncogenic transformation (84), we studied whether Ad-induced 
cyclin E may target and activate CDK2 in virus-infected cells for productive Ad 
replication.  
 
We first examined the physical interaction between virus-induced cyclin EL and 
CDK2. The results indicated that Ad-induced cyclin EL preferentially associates 
with CDK2 protein (Fig. 2.2). We cannot exclude that endogenous cyclin E in 
A549 cells may also interact with CDK2; however, we observed that the increased 
CDK2 in the cyclin E/CDK2 immunocomplexes was associated with cyclin EL 
induction after infection with replication-competent Adwt and Adhz63. The results 
suggested cyclin EL highly interacts with CDK2 in Ad-infected cancer cells. In 
proliferating cells, the abundance of the cyclin E protein directly links to the 
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formation of active cyclin E/CDK2 complex (80, 142). With an intact cyclin box and 
the C-terminal 50 amino acids, the full-length cyclin EL is able to bind and activate 
CDK2 as cyclin E (82, 84). Consistent with our finding, previous studies showed 
that the addition of exogenous cyclin EL increases the formation of cyclin 
EL/CDK2 complex correlating to the increased activity and phosphorylation of 
CDK2 in human lung fibroblasts (80) and breast cancer cells (143). We reason 
that Ad-induced cyclin EL may have a strong affinity to CDK2 in the cellular 
environment affected by Ad infection.  
 
We identified that Ad-induced cyclin EL correlates with the increase in 
phosphorylation of CDK2 at T160 and pRb at S612 (Figs. 2.3B and 2.4A). Three 
phosphorylation sites have been identified in CDK2 (125). T160 phosphorylation 
is essential for CDK2 activity, while T14 and Y15 phosphorylation cause an 
inhibitory effect. The retinoblastoma tumor suppressor pRb is inactivated by 
CDK’s phosphorylation and enables E2F transcription factor to be released from 
the pRb/E2F complex to carry out the downstream gene regulation (144, 145). 
Phosphopeptide analysis of pRb showed that S612 is one of the CDK2-preferred 
phosphorylation sites (130). We also examined the level of pRb with 
phosphorylation of T821 (CDK2-preferred) and S795 (CDK4-preferred); we did 
not detect any significant change at either of these two sites (Fig. 2.4A). Inhibition 
of CDK2 expression with the CDK2 siRNA repressed phosphorylation on CDK2 
and pRb (Fig. 2.7D) and decreased viral replication (Fig. 2.7C). These results 
indicate that Ad-induced cyclin EL activates CDK2 by phosphorylating at T160, 
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which then specifically introduces pRb phosphorylation at the S612 site.  
 
The pRb phosphorylation by cyclin EL/CDK2 may lead to regulation of multiple 
cellular and viral genes for productive Ad replication. Interestingly, Ad-induced 
cyclin EL expression was also inhibited by a CDK2 chemical inhibitor and CDK2 
siRNA (Figs. 2.6C, 2.7D and 2.8E). It seems that inhibition of CDK2 interferes in 
the cyclin E induction via a loopback regulation (Fig. 2.9). Previous studies have 
reported that cyclin E gene is the downstream target of E2F (146, 147). In our 
previous work, we showed that the cyclin E promoter is more active in cancer 
cells and the promoter activity is further enhanced after Ad infection (56). We 
suggest that cyclin EL activates the cyclin EL-CDK2-pRb/E2F pathway and cyclin 
EL itself is also one of the targets of the pathway.  
 
We detected a notable decrease of CDK inhibitors p21 and p27 in the Ad-infected 
cells. p21 and p27 inhibit the activity of cyclin/CDK complexes to prevent the 
cell-cycle progression, and their protein stability is also regulated by cyclin/CDK 
complexes (134, 148, 149). Phosphorylation of p27 by cyclin E/CDK2 causes p27 
degradation (148, 150). Montagnoli et al. (1999) showed that cyclin 
E/CDK2-dependent phosphorylation of p27 at threonine 187 facilitates the 
formation of a trimeric complex with cyclin E/CDK2 and leads to p27 ubiquitination 
(151). In agreement with our findings, recent studies also suggest that CDK may 
promote p21 degradation (149, 152). Thus, the activated cyclin E and CDK2 may 
decrease the CDK inhibitors p21 and p27 to benefit viral replication.  
 62 
 
In summary, our results showed that Ad-induced cyclin EL binds to and activates 
CDK2 that subsequently phosphorylates the transcriptional suppressor pRb, 
which can regulate expression of multiple cellular and viral genes, including cyclin 
E (Fig. 2.9). Our previous studies have shown that Ad E1B55K has a function to 
enhance cyclin E induction. In cancer cells, this E1B55K function is not critically 
required for cyclin E induction and viral replication, likely because of deregulated 
cyclin E expression or having E1B55K-like cancer cellular factors. This study 
demonstrated that Ad-induced cyclin EL plays a critical role in Ad replication 
through activation of CDK2 that generates a suitable environment for viral 
replication. Our study reveals a new molecular basis for Ad replication in cancer 





ONCOLYTIC ADENOVIRUS TARGETS CYCLIN E OVEREXPRESSION AND 
INHIBITS TUMOR DEVELOPMENT IN VIVO 
 
3.1. Introduction 
Oncolytic virotherapy with self-replicating and cancer-selective viruses has 
emerged as a new hope for cancer treatment. The therapeutic effects of oncolytic 
viruses are initiated from small amount of viruses and spread to surrounding 
tumor cells, and thus has been considered as an attractive drug platform (4, 153). 
Gene-attenuated replication-competent adenovirus (Ad) ONYX-015/dl1520 has 
been applied to several preclinical (16, 36, 154) and clinical studies in the United 
States (17, 18). With the structure similar to dl1520 and slight modification, H101 
has been commercially approved for cancer treatment in China. 
 
Although dl1520 has achieved some measure of success in solid tumor treatment, 
the native E1a promoter on dl1520 is constitutively active and thus leads to the 
safety concerns that virus may replicate in normal cells to cause toxicity (155-157). 
The major strategy to increase tumor specific replication of oncolytic Ads depends 
on transcriptionally regulating the essential E1A expression by tumor-specific 
promoters (6, 158). The proteins encoded by the E1a region are expressed 
immediately after infection, and these gene products modulate the cell cycle, 
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recruit cellular proteins, and produce viral proteins to process viral DNA replication 
(37). By replacing native E1a promoter with cellular promoter preferentially active 
in tumor rather than normal tissues, oncolytic Ads can carry out more selective 
replication restricted in tumors. Some tumor-specific promoter based oncolytic 
Ads such as human telomerase reverse transcriptase (hTERT)-promoter driven 
OBP-301 (Telomelysin) (32) and prostate-specific antigen (PSA)-promoter driven 
CV706 (29) have been evaluated in clinical trials. Nevertheless, most known 
tumor-specific promoters are only active in a narrow range of tumors with relative 
weak activity compared with the constitutive viral promoters which are 
ubiquitously active (159-163). Also, our published microarray study indicates virus 
infection causes strong repression of various cellular promoters (79). Lacking 
consideration for the negative effects imposed by virus infection on those 
promoters may narrow our insight and thus hinder the future vector design. 
 
Cyclin E is known to regulate cell cycle progression (80), DNA replication (110, 
111), and centrosome duplication (112, 113). Numerous types of cancers such as 
lung cancer and breast cancer are highly associated with dysregulation of cyclin E 
(87). Constitutive overexpression of cyclin E induces chromosome instability (89, 
90), impairs normal cell cycle progression and triggers tumorigenesis in 
transgenic animal models (86, 114, 115). Previously we have demonstrated that 
cyclin E overexpression is a molecular basis of selective oncolytic replication of 
E1b55K-deleted Ads in human cancer cells (56, 79). Ads induce cyclin E which 
activates CDK2 that targets the transcriptional repressor pRb, turning on the 
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downstream gene expression to adjust the cellular environment for productive 
viral replication (164). We also reported that cyclin E promoter, highly active in 
cancer cells, is further augmented during viral reproduction process (56, 165). 
The unique properties of cyclin E promoter in virus replication indicate its potential 
on the oncolytic vector design. Based on these findings, we generated a novel 
E1b-deleted Ad-cycE in which the E1a gene is under the control of the human 
cyclin E promoter. E1A expression driven by the cyclin E promoter in Ad-cycE can 
be enhanced by dual pathways. Since the cyclin E promoter is already highly 
active in many types of cancer cells, the initial E1A expression will be driven by 
activation of cyclin E promoter by cancer cellular factors, leading to selective viral 
replication. The activity of cyclin E promoter can also be further augmented by Ad 
itself as we have shown that cyclin E expression is significantly upregulated in 
















Figure 3.1. Proposed rationale of activating E1A transcription in Ad-cycE 
vector. Ad-cycE is an E1b-deleted oncolytic Ad carrying a cyclin E promoter 
(cycE-P) to drive an intact E1A expression cassette. With dual properties to target 
the cyclin E overexpression in cancer cells and virus-induced environment, cyclin 
E promoter may allow either the cellular factors from cancer cells or the viral 
factors from viral reproduction process to activate virus E1A transcription in 
Ad-cycE. 
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Our results revealed that a novel therapy Ad-cycE targets cyclin E overexpression 
in cancer cells, significantly represses tumor growth and prolonged survival of 
nude mice bearing human lung cancer xenograft. The vector also shows selective 
and efficient antitumor effects on cancer cell lines reported as non-permissive for 
dl1520 replication. This study not only provided the attractive insight for the future 
design of the oncolytic Ad vectors, but also unraveled the potent antitumor 
efficacy by targeting cyclin E overexpression in cancer cells and viral reproduction 
process. 
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3.2. Materials and Methods 
Cell lines and culture conditions. Human embryonic kidney HEK 293 (ATCC no. 
CRL-1573), lung fibroblast WI-38 (ATCC no. CCL-75), lung cancer A549 (ATCC 
no. CCL-185) and H1299 (ATCC no. CRL-5803), prostate cancer DU-145 (ATCC 
no. HTB-81) and LNCaP (ATCC no. CRL-1740), osteosarcoma Saos2 (ATCC no. 
HTB-85), and breast cancer MDA-MB-231 (ATCC no. HTB-26) cell lines were 
purchased from the American Type Culture Collection (Rockville, MD). HEK 293, 
A549 and MDA-MB-231 cells were cultured in DMEM. Saos 2 cells were cultured 
in McCoy's 5A. LNCaP and H1299 cells were cultured in RPMI-1640 medium. 
WI-38 cells were cultured in minimal essential medium (MEM) Alpha GlutaMAX 
with 0.1 mM non-essential amino acids and 1.0 mM sodium pyruvate. All media 
were supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at 
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD) and 
Corning Cellgro (Manassas, VA). 
 
Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was 
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1 
deletion carrying a green fluorescent protein (GFP) constructed in our laboratory 
(166), was used as a replication-defective control. Ad dl1520 is a E1b55K mutant 
which contains an 827-bp deletion and a point mutation to generate a premature 
stop codon in the E1B55K coding region (15). Adhz55 is a E1b-deleted oncolytic 
vector carrying prostate-specific ARR2PB promoter (167) driving an intact E1A 
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expression cassette constructed in our laboratory. Ad-cycE is a novel E1b-deleted 
oncolytic vector carrying a human cyclin E promoter driving an intact E1A 
expression cassette. To prepare Ad-cycE vector, 671 bp of human cyclin E 
promoter (GenBank ID: X95406) (168, 169) was released by digesting 
pGL-2-cycE promoter 10-4 plasmid (Addgene, Cambridge, MA) with SmaI and 
the fragment was ligated into the shuttle plasmid pMEa301 which contains 
promoterless E1a region and the deletion of E1b to generate pBZ400 plasmid. 
The pBZ400 plasmid contains cyclin E promoter, together with entire E1a open 
reading frame and E1b deletion. pBHGE3 plasmid (122) containing Ad genomic 
DNA and pBZ400 plasmid were cotransfected into 293 cells. Ad-cycE was 
rescued from cells after transfection and contains a human cyclin E promoter to 
control E1a open reading frames (ORF) with the deletion of E1b region. All of the 
vectors created and used in this study are based on the backbone of wild-type Ad 
type 5.  
 
Cytotoxicity assay. Cells were seeded into 24-well plates at a density of 
2.5 x 104 (cells/well) and cultured under the indicated conditions. Cytotoxicity was 
assessed with crystal violet staining (170). Cells were fixed with 3.7% 
paraformaldehyde and stained with 1% crystal violet followed by washing with 
water to remove excess dye. The dye was solubilized with 2% SDS and the 
absorbance of the solubilized stain was measured at 590 nm using a Synergy HT 
Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The OD values were 
quantitated into the cell viability % by the formula, cell viability % = (OD value of 
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experimental group / OD value of control group) x 100%. The mock-control group 
was calculated as 100% of cell viability in the assay (171).  
 
Western blot analysis. Infected cells were harvested at indicated time points and 
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium 
vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as 
described previously (123). Briefly, 80 µg of cell lysates were electrophoresed 
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P 
Membrane (Millipore, Billerica, MA). The primary antibodies used in this study 
were rabbit anti-cyclin E (M-20), (Santa Cruz Biotechnology, Santa Cruz, CA), 
mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA). Actin was 
used as an internal control. The membranes were then incubated with anti-mouse 
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific 
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection 
was performed with ECL reagents according to the supplier’s recommendations 
(GE Healthcare).  
 
Viral titration. Total infected cells and culture supernatants were collected at the 
indicated time points and lysed to release virus particles with three cycles of 
freezing and thawing. The viral titers were determined by the infective unit method 
as described previously (120, 121). Briefly, HEK 293 cells were seeded in 96-well 
plates at a density of 103 (cells/well) and then infected with 10-fold serially diluted 
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viruses. CPE was recorded and scored after incubation for 7 days.  
 
Lung cancer xenograft study. Female athymic nude mice (NCr-nu/nu) were 
obtained from National Cancer Institute (Bethesda, MD). 5 x 106 A549 human 
lung cancer cells were subcutaneously injected into the flanks of mice (aged 6 
weeks). Once palpable tumors were established (mean of tumor sizes 
approximates to 20-25 mm3), the mice were randomized and received 5 × 108 IFU 
of AdGFP or Ad-cycE in 50 μL PBS every 2 days for total 4 treatments. The 
tumors were measured every 3 days until the tumor volume was greater than 
1000 mm3. The tumor volume was determined by externally measuring in 2 
dimensions with a caliper and calculated based on the following equation: V = (L 
X W2) / 2, where L is length and W is width of the tumor. Animal experiments were 
performed according to the institutional guidelines approved by the University of 
Louisville Institutional Animal Care and Use Committee. Survival data were 
plotted based on Kaplan-Meier method, followed by the analysis of log-rank test 
with SPSS statistical software (version 19.0; SPSS, Inc., Chicago, IL) (172). 
 
Immunohistochemistry. Tumors were harvested one week after the fourth 
treatment in vivo, embedded in optimal cutting temperature compound (O.C.T.) 
(Sakura Finetek, Torrance Ca), and stored at -20°C. The tumor sections and 
immunohistochemical staining were performed as previously reported (173). 
Briefly, slides were air-dried, fixed in cold acetone at 4°C for 20 min. The 
endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 10 
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mins and washed with PBS three times, followed by incubation with SuperBlock 
(37515, Pierce Biotechnology, Rockford, IL) at room temperature for 30 min. All 
antibodies were applied in SuperBlock. Sections were incubated with 
goat-anti-adenovirus polyclonal antibody (AB1056, Millipore, Billerica, MA), 
diluted 1:800, for 1 hr at room temperature. The antibody staining signals were 
amplified by a biotinylated anti-goat IgG diluted 1:200 in conjunction with 
VECTASTAIN avidin-biotin complex method kit (Vector Laboratories, Burlingame, 
CA). Visualization was achieved using 3,3-diaminobenzidine tetrahydrochloride 
(ImmPACT DAB peroxidase substrate; Vector Laboratories). Slides were 
counterstained with hematoxylin and photographed at X200 and X400 
magnification and in an Olympus BX53 microscope (Olympus, Center Valley, PA). 
 
Statistical analyses. All above experiments, except specifically indicated, were 
repeated at least three times. Quantitation results were reported as means ± 
standard deviation (S.D.). Statistical difference of the combination experiment was 




Ad-cycE induces more significant oncolytic effects on prostate cancer cells 
than prostate cancer-specific oncolytic Adhz55. Ad-cycE is an E1b-deleted 
vector with the cyclin E promoter to replace the endogenous Ad E1a promoter. 
We compared Ad-cycE with Adhz55 which has the prostate cancer-specific 
ARR2PB promoter driving Ad E1a gene (167). Non-replicative AdGFP was used 
as a negative control, and wild-type Ad 5 (Adwt) was used as the positive virus 
replication control. We first examined the E1A expression at 24 hr p.i. in LNCaP 
and DU-145 prostate cancer cells. Cells were infected with AdGFP, Adwt, Adhz55 
or Ad-cycE at 5MOI. With the same infection condition, the E1A expression of 
Ad-cycE was higher than that of Adhz55 in LNCaP and DU-145 prostate cancer 
cell lines (Fig. 3.2A, comparing lanes 3 and 4, 7 and 8). We then examined the 
cytotoxicity of Adhz55 and Ad-cycE on these two prostate cancer cell lines. Cells 
were infected with Adwt, Adhz55, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4, 8 MOI for 
96 hr and the cytotoxicity were determined by crystal violet staining. Figure 3.2B 
showed that AdGFP did not induce significant cytotoxicity at different MOIs. Both 
LNCaP and DU-145 prostate cell lines were sensitive to Adwt and Ad-cycE 


















Figure 3.2. Comparison of prostate cancer-promoter driven Adhz55 and 
cyclin E-promoter driven Ad-cycE in prostate cancer cells. (A) LNCaP and 
DU-145 Cells were infected with AdGFP, Adwt, Adhz55 or Ad-cycE at 5 MOI and 
collected at 24 hr p.i., respectively. The cell lysates were immunoblotted for E1A 
and actin. Actin was used as a loading control. (B) Cells were seeded at a density 
of 2 x 104 and infected with Adwt, Adhz55, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4, 
and 8 MOI for 72 hr. Cytotoxicity were determined with crystal violet staining and 
photographed. Data are representative examples of three independent sets of 
experiments and quantitated as cell viability %. The values represent the means ± 
S.D. of independent triplicate compared with the AdGFP-infected group of each 
dose.
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Ad-cycE selectively destroys lung cancer cells and spares noncancerous 
lung cells. The oncolytic selectivity of Ad-cycE was determined with human A549 
lung cancer cells and WI-38 noncancerous lung fibroblast. A549 cell line is a 
human lung cancer cell line with dysregulated cyclin E that can be significantly 
induced after Ad infection (56); WI-38 cell line has the properties of primary cells 
with a finite lifetime of 50 population doublings (174). As we mentioned above, 
AdGFP and Adwt were used as a negative and positive replication control, 
respectively. As E1b55K-deleted dl1520 with the native E1a promoter can 
replicate in different types of cancer cells, we particularly applied it as the 
oncolytic Ad control. Cytopathic effects (CPE), the classical characteristic of 
oncolytic virus replication, were recorded on Figure 3.3, showing morphological 
change as infected cells rounded up and detached from the cell monolayer. 
Without replication, AdGFP did not induce CPE on either WI-38 or A549 cells. 
Wild-type virus (Adwt) non-selectively induced CPE in both noncancerous WI-38 
and A549 lung cancer cells; however Ad-cycE only induced significant CPE on 
A549 lung cancer cells but not on WI-38 cells as well as dl1520. In noncancerous 
WI-38 cells, Adwt significantly decreased cell viability to 30% (P = 0.0000047, 
compared with the AdGFP-infected group), while dl1520 and Ad-cycE do not 
cause significant changes (P = 0.28 and 0.2, compared with the AdGFP-infected 
group respectively). In A549 cells, Adwt decreased cell viability to 6%, while 
dl1520 and Ad-cycE decreased cell viability to 40% and 25%, respectively. It 






Figure 3.3. Cytopathic effects of human Ads on WI-38 and A549 cells. (A) 
Cells were infected with AdGFP, Adwt, dl1520 or Ad-cycE at 8 (for WI-38) or 5 
MOI (for A549). CPE was observed at 72 hr p.i and photographed with an inverted 
microscope Olympus CKX41. The cell viability % was determined and the values 
represent the means ± S.D. of independent triplicate compared with the 
AdGFP-infected group.  
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Replication of Ad-cycE is activated in cancer cells. Ad E1A is the crucial 
protein which initiates the whole virus replication process and promotes cells to 
enter S phase (37). With E1a ORF under control of cyclin E promoter, we 
hypothesized that E1A transcription in Ad-cycE is activated in cancer cells with 
cyclin E overexpression. A549 cells were infected with AdGFP, Adwt, dl1520 or 
Ad-cycE at 5 MOI for 24 hr. As Figure 3.4A shown, no E1A expression was 
detected in non-replicative AdGFP with the deletion of E1 region whereas the E1A 
expression of Ad-cycE was detected in A549 cells at a similar level to dl1520 and 
Adwt at 24 hr postinfection (p.i.), suggesting E1A transcription of Ad-cycE is 
activated in A549 cells. To determine whether the activation of E1A transcription 
leads to Ad-cycE replication, virus production was monitored over time. The data 
showed that virus yield of Ad-cycE increased over time as well as Adwt and 
dl1520 (from 6.7 X 105 at 0 hr to 8.3 X 108 at 72 hr) (Fig. 3.4B). Taken these data 



















Figure 3.4. The expression of viral E1A and virus production in A549 cells. 
(A) Cells were infected with AdGFP, Adwt, dl1520 or Ad-cycE at 5 MOI and 
collected at 24 hr p.i. The cell lysates were immunoblotted for E1A protein and 
actin. Actin was used as a loading control. (B) The virus yields were determined at 
0, 24, 48, and 72 hr p.i. with the infection unit method. The values represent the 
means ± S.D. of independent triplicate. 
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Oncolytic efficacy of Ad-cycE on multiple cancer cell lines. To detect the 
cytotoxicity of Ad-cycE, human A549 and H1299 lung cancer, MDA-MB-231 
breast and Saos 2 osteosarcoma cancer cells were infected with Adwt, dl1520, 
Ad-cycE and AdGFP at the indicated MOI for 72-96 hr and stained with crystal 
violet (Fig. 3.5). As a positive control, Adwt widely induced strong oncolysis in all 
cancer cell lines whereas a non-replicative control AdGFP did not cause oncolysis. 
A significant cytotoxicity was observed in all cancer cell lines infected with 
oncolytic dl1520 or Ad-cycE when compared to cells infected with non-replicative 
AdGFP. Cell viability was then quantified and each group was compared to the 
mock-infected group. In Saos 2 osteosarcoma and MDA-MB-231 breast cancer, 
Ad-cycE worked even better than dl1520 (Fig. 3.5, Boxed). This experiment 
showed that in addition to lung cancer cells, Ad-cycE can efficiently destroy a 









Figure. 3.5. Cytotoxicity of Ad-cycE in multiple cancer cell types. A549, 
H1299, Saos2, and MDA-MB-231 cells were seeded at a density of 2-5 x 104 and 
infected with Adwt, dl1520, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4, and 8 MOI for 
72-96 hr. Cytotoxicity were determined with crystal violet staining and 
photographed. Data were quantitated as cell viability % values. The quantitated 
data of boxed areas indicated that with 2 MOI of virus infection, dl1520 decreased 
the cell viability of A549 to 87% while Ad-cycE decreased it to 76%; dl1520 
decreased the cell viability of H1299 to 65% while Ad-cycE decreased it to 78%; 
dl1520 decreased the cell viability of MDA-MB-231 to 83% while Ad-cycE 
decreased it to 59%; dl1520 decreased the cell viability of Saos2 to 92% while 
Ad-cycE decreased it to 77%. 
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Ad-cycE suppresses tumor growth in athymic nude mice. The therapeutic 
effects of Ad-cycE were further examined in the lung cancer subcutaneous 
xenograft model. Once palpable tumors were established, the mice were 
randomized and 5 × 108 IFU of AdGFP or Ad-cycE in 50 μL PBS was injected 
intratumorally every 2 days for total 4 treatments. The tumor sizes of mice were 
monitored over the time and the death of mice was recorded. The initial reduction 
of tumor volumes in Ad-cycE treated group was observed at day 9 after the first 
treatment. Mice treated with Ad-cycE exhibited significant suppression of tumor 
growth with 95% reduction in the mean tumor volume as compared with mice 
treated with control AdGFP at day 51 after the first treatment (P = 0.0008, Fig. 
3.6A). Once the tumor volume exceeded 1000 mm3, the mouse was sacrificed. 
The representative photographs of mice at the day of sacrifice revealed that in 
AdGFP-treated groups, tumor kept growing while Ad-cycE treatment suppressed 
tumor growth (Fig. 3.6B). In the Ad-cycE-treated group with total seven mice, two 
of them were tumor free after the treatment (no longer visible), three had 
decreased tumors all the time during the 130 days of follow-up, and two mice had 
recurring tumor growth at around 30 days after the first treatment (Fig. 3.6C). In 
an additional experiment, tumors from the mice that were injected with AdGFP or 
Ad-cycE were harvested 7 days after the last treatment and analyzed with 
immunohistochemical analysis to detect hexon protein expression. Hexon 
proteins, as the major coat protein of Ad capsids, represent the classic marker of 
virus particles (175). Hexon proteins were stained as the brown dots and localized 
within the cytoplasm (Fig. 3.6D, panel c and d). The results indicated a higher 
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level of hexon expression in the tumor sections generated from A549 cell 
xenograft treated with Ad-cycE, suggesting the virus replicated within tumor 
tissues. The results reported here clearly demonstrate that Ad-cycE replicates in 
tumor tissues and strongly inhibits tumor growth, resulting in prolonged mice 












































































































Figure 3.6. In vivo antitumor effects of Ad-cycE on subcutaneous A549 
human lung cancer in nude mice. Mice carrying established A549 tumors were 
treated with control virus AdGFP (n=6) or Ad-cycE (n=7) on days 0, 2, 4, and 6. 
The total viral dose was 2 x 109 IFU / mouse. (A) The vertical arrow represents 
each treatment. Tumor volume (V) was plotted against time and was determined 
by the equation V = (L x W2) / 2, in which L represents the length, and W 
represents the width of the tumor. The values represent the means produce ± S.D. 
* P<0.05 compared with AdGFP control group, Student’s t-test. (B) 
Representative mice from each group were photographed at the time of sacrifice. 
(C) Kaplan-Meier survival curves were plotted for both treatments (AdGFP n = 6, 
Ad-cycE n = 7, P < 0.05, log-rank test). (D) Polyclonal antibody anti-adenoviral 
hexon was used to detect the production of adenoviral particles in tissue sections 
after treatment. The representative photographs were taken at original 
magnification X200 or X400 
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3.4. Discussion 
One of the significant features of cyclin E is its differential expression in cancer 
and normal cells. While dramatic overexpression of cyclin E has been detected in 
numerous cancers, the expression levels of cyclin E are repressed in most 
nondividing normal cells (87). We previously have shown that cyclin E promoter is 
highly active in cancer cells and the promoter activity is further augmented during 
viral reproduction process (56, 165). The aim of this study was to evaluate a novel 
oncolytic Ad-cycE driven by the human cyclin E promoter with an entire 
E1b-deleted backbone. To date, none of known designs of tumor-specific 
oncolytic adenovectors took the virus-induced environment into consideration. 
This is the first oncolytic adenovector using a human cyclin E promoter combined 
with the strategy of entire E1b-deletion. As the replication of Ad-cycE depends on 
the activation of cyclin E promoter, the oncolysis of Ad-cycE is enhanced in 
cancer cells and repressed in normal cells. Our data showed that Ad-cycE 
selectively replicated in multiple cancer cells and inhibited the in vivo tumor 
growth in nude mice bearing lung cancers, leading to the prolonged survival time. 
 
Most of the tumor-specific oncolytic adenoviruses are developed based on the 
promoters preferentially active in a specific type of cancers (158). Although 
regulating the viral gene expression by tumor-specific promoters is feasible, this 
approach can be hindered by the relatively weak activity (159-163) or 
virus-induced repression (79) on many tumor-specific promoters. Similar 
phenomenon was observed when we constructed prostate cancer-specific 
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oncolytic Adhz55. We noticed that this kind of tumor-specific promoter somewhat 
may not drive E1A expression as well as constitutive viral promoters. Compared 
to prostate cancer specific promoter-based Adhz55, human cyclin E 
promoter-based Ad-cycE elicits better efficacy (Fig. 3.2). Also, the oncolytic 
efficacy of Ad-cycE was observed in different type of cancer cells (Fig. 3.5). 
Previously we have demonstrated that dl1520 can induce cyclin E overexpression 
in the permissive cancer cells that support dl1520 replication but not in the 
restrictive cancer cells that are resistant for dl1520 replication (56). Here we 
noticed that the oncolysis induced by Ad-cycE is not only restricted in the reported 
permissive lung cancer cells A549 and H1299. In the reported restrictive cancer 
cells for dl1520 replication, Ad-cycE elicited better oncolytic efficacy than dl1520. 
While the exact mechanism(s) to induce oncolysis by Ad-cycE in the restrictive 
cancer cells for dl1520 replication remains to be investigated, it is possible that 
cyclin E promoter activated after Ad infection may benefit Ad-cycE replication in 
those restrictive cancer cells. We have reported that the activity of cyclin E 
promoter is enhanced during viral reproduction process (56, 165), and 
virus-induced cyclin E activates the cyclin EL-CDK2-pRb/E2F pathway to 
enhance cyclin E expression via a loopback regulation (164). We postulate that 
oncolytic adenovirus driven by human cyclin E promoter may have a broader 
range of application since it can be activated in cancer cells with dysregulated 
cyclin E and the promoter activity can be further enhanced by virus reproduction. 
 
The mechanism(s) of Ad-cycE induced oncolysis requires further studies. The 
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oncolysis mediated by Ad-cycE may correlate with multiple mechanisms such as 
virus replication, apoptosis, and autophagy. The virus replication and release from 
cells can directly cause cell lysis as the major mechanism (7, 176). Also, studies 
by our laboratory as well studies by others’ have shown that oncolytic Ads with 
entire E1b deletion induce more apoptosis compared to E1b55K-deleted dl1520 
and wild-type Ad (38, 177). The expression of E1a gene has been shown to 
trigger the accumulation of p53 protein, resulting in p53-dependent apoptosis (40, 
106). Due to the lack of E1b19K to repress E1A-induced apoptosis, Ad-cycE may 
induce more apoptosis than dl1520. Additionally, previously we have shown virus 
replication induces autophagy to promote virus replication and oncolysis (166). 
Autophagy is a process involving in the lysosomal degradation, recycling of 
cellular components and type II programmed cell death (178, 179). Currently we 
have studied the mechanism of Ad-cycE-induced oncolysis and are observing 
Ad-cycE induced LC3-I to LC3-II cleavage and ATG 5-12 complex formation, 
suggesting that this process may also participate in Ad-cycE-induced oncolysis 
(Cheng and Zhou, unpublished data). 
 
We extended our findings from in vitro studies to evaluate antitumor effects of 
Ad-cycE in a human lung cancer xenograft mouse model, which confirmed the 
potent antitumor efficacy elicited by Ad-cycE in vivo. A long-term survival animal 
study also allowed us to follow up the responses of individual mice to the Ad-cycE 
treatment. The tumors in Ad-cycE-treated mice started shrinking at day 9. 
However, during the long-term follow up (over 100 days) we noticed that each 
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mouse had individual response to the Ad-cycE treatment. In Ad-cycE-treated 
group, two mice had invisible tumor at the end of the study; three mice had 
repressed tumor growth all the time; two mice had repressed growth for around 20 
days but tumors recurred at around 30 days after the first treatment. It should be 
noticed that if virus treatment cannot completely eliminate the tumor mass, the 
remnant tumor cells may recur as what may happen in the clinical setting. The 
variances among the outbred athymic NCr-nu/nu mice may be one important 
determinant for the fates of tumor repression or recurrence. Our observation 
pointed out the importance of personalized treatment in the oncolytic virotherapy. 
Individual response to oncolytic virotherapy should be taken into consideration to 
develop the strategy to achieve better therapeutic outcomes. 
 
In conclusion, in the present study we have shown that human cyclin E promoter 
driven Ad-cycE exhibits potent antitumor efficacy in vitro and in vivo. Our study is 
the first to demonstrate the application of cyclin E promoter-based vector design 
with dual properties to target the cyclin E overexpression in cancer cells and 
virus-induced environment. As cyclin E is highly overexpressed in a variety of 
cancers and further augmented during virus reproduction, Ad-cycE represents 
tumor specificity and potential to overcome restriction in nonpermissive cancer 
cells for dl1520. Further studies will help for characterizing the clinical importance 
of Ad-cycE in the future cancer treatments.
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CHAPTER IV 
PROPERTIES OF ONCOLYTIC REPLICATION OF ADENOVIRUSES IN 
MURINE AND HUMAN LUNG CANCER CELLS 
 
4.1. Introduction 
Human adenoviruses (Ads) are double-stranded linear DNA viruses. The viral 
genes are divided into early and late genes relative to the onset of viral gene 
expression. Ads with deletion of the early E1B55K gene preferentially replicate in 
cancer cells and cause oncolysis, leading to the release of amplified and 
infectious viruses to further destroy tumor cells (5). Studies by our laboratory as 
well studies by others’ have shown that oncolytic Ads can efficiently kill cancer 
cells in cell culture and strongly inhibit tumor growth in animal experiments (38, 
121, 180, 181). E1b55K-deleted ONYX-015 (dl1520) has been applied in clinical 
trials in the United States and H101 (with the similar structure as ONYX-015) has 
been commercially approved for cancer therapy in China (17, 18). However, the 
antitumor effects of oncolytic Ads have been somewhat disappointing when used 
in clinical applications (182, 183).  
 
Current animal models used to evaluate the efficacy of oncolytic Ads rely on 
human tumor xenograft in immunodeficient mouse models. However, human 
tumor xenograft models are less clinically relevant to the real cancers in patients. 
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Human Ads tend to target human tumors and replicate more efficiently in human 
cells than in murine cells. Thus preclinical results obtained with human tumor 
xenograft in mouse models may overstate the therapeutic efficacy. Additionally, 
the lack of functional immune systems in immunodeficient models may hinder the 
accuracy of clinically predicting the effects in patients (3, 184). Ads have complex 
interactions with host cell immune response effectors (17, 185). In the presence of 
the immune system, the oncolytic effects of the virus may be reduced due to the 
immune responses against viral particles. Conversely, the immune system may 
help the tumor-killing effects by recruiting nature killer cells, antibodies, 
tumor-specific cytotoxic T lymphocytes (CTLs) to enhance the therapeutic 
outcome (186). Development of immunocompetent mouse models with murine 
tumor cells in which oncolytic Ads can selectively replicate is necessary and 
important.  
 
Previously we have demonstrated that cyclin E overexpression is a molecular 
basis of selective replication of E1b55K-deleted Ads in human cancer cells (56, 
79). Ad replication depends on cyclin E induction in cells after Ad infection. 
E1b55K-deleted Ads fail to efficiently induce cyclin E expression in the normal 
cells, leading to the restricted replication. However, this E1B55K function is not 
required in cancer cells which generally already have dysregulated cyclin E; 
therefore E1b55K-deleted Ads can successfully replicate in cancer cells and 
cause oncolysis. We recently further reported that Ad-induced cyclin E 
overexpression adjusts the cellular environment for viral productive replication via 
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activating CDK2, that in turn targets the transcriptional repressor pRb and 
regulates cell cycle progression (164). 
 
Cyclin E is a nuclear protein essential for the cell cycle progression (80), DNA 
replication (110, 111), and centrosome duplication (112, 113). The protein level of 
cyclin E rises at late G1 phase and peaks at the G1/S phase to promote S-phase 
entry in normal cell cycle (80, 81). Numerous types of cancers are highly 
associated with dysregulation of cyclin E, such as cyclin E gene amplification (91), 
overexpression of mRNA or protein levels (87, 92), decrease of cyclin E protein 
turnover (93, 94), or the presence of more active forms of cyclin E (94-96). 
Constitutive overexpression of cyclin E induces chromosome instability (89, 90), 
impairs normal cell cycle progression and triggers tumor development in 
transgenic animal models (86, 114, 115). Human cyclin E overexpression in 
mouse lung leads to development of premalignant and malignant lung lesions 
which resemble to the features found in lung cancer patients (88, 115). Murine 
ED-1 cell line was derived from the lung cancers of cyclin E transgenic mice (187). 
As oncolytic Ad replication is related to dysregulated cyclin E expression, Ads 
may selectively replicate in murine ED-1 cancer cells.  
 
Replication of human wild-type Ad5 and oncolytic Ads in murine ED-1 cells was 
studied and compared with human lung cancer A549 cells which overexpress 
cyclin E. The oncolytic effects of one novel oncolytic Ad-cycE driven by cyclin E 
promoter (169) on murine ED-1 lung cancer cells was characterized in this study 
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along with dl1520. Our results showed that human Ads can penetrate ED-1 cells 
which have the ability to support viral DNA synthesis, early and late gene 
expression, and virion production. Although with relatively lower production 
compared to in human cells, the pattern of virus replication in murine ED-1 cells is 
similar to that in human A549 cells. This study indicates that ED-1 cancer cell line 
is permissive for human Ad replication and can be used to develop a new 
immunocompetent murine tumor model for evaluating the therapeutic efficacy of 
oncolytic Ads. 
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4.2. Materials and Methods 
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), human lung 
cancer A549 (ATCC no. CCL-185) and mouse embryonic fibroblast NIH/3T3 
(ATCC no. CRL-1658) cell lines were purchased from the American Type Culture 
Collection (Rockville, MD). Murine ED-1 cells line, a lung cancer cell line derived 
from transgenic mice with wild-type human cyclin E (88, 187), was a gift from Dr. 
Ethan Dmitrovsky and further single-cell subcloned in our laboratory. HEK 293 
and A549 cells were cultured in minimal essential medium Alpha. ED-1 cells were 
cultured in RPMI-1640 medium. All media were supplemented with 10% fetal 
bovine serum (FBS) and penicillin/streptomycin (100 U/ml). Cells were cultured in 
a 5% CO2 incubator at 37°C. All cell culture reagents were obtained from Gibco 
BRL (Bethesda, MD) and Corning Cellgro (Manassas, VA).  
 
Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was 
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1 
deletion carrying a green fluorescent protein (GFP), was used as a 
replication-defective control. Ad dl1520 is a E1b mutant which contains an 827-bp 
deletion and a point mutation to generate a premature stop codon in the E1B55K 
coding region (15). Ad-cycE is a novel E1b-deleted oncolytic vector carrying a 
human cyclin E promoter driving an intact E1A expression cassette. The 
endogenous E1a promoter was deleted and a human cyclin E promoter 
(GenBank ID: X95406) was inserted to replace the deleted E1a promoter in 
Ad-cycE. Therefore, Ad-cycE contains a human cyclin E promoter to control E1a 
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open reading frames (ORF) (169). All of the vectors created and used in this study 
are based on the backbone of wild-type Ad type 5. 
 
MTT assay. Cells were seeded into 24-well plates at a density of 2.5 x 104 
(cells/well) and cultured under the indicated conditions. Cell proliferation was 
assessed at three days after respective treatments by measuring the conversion 
of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
purple formazan, according to the manufacturer's instructions (Boehringer 
Mannheim, Indianapolis, IN). The absorbance of the supernatant was measured 
at 590 nm using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek, Winooski, 
VT). The results were expressed as the fold change relative to the result at day 0. 
Doubling time was analyzed from the curves of cell growth in log phase with the 
exponential regression analysis provided by http://www.doubling-time.com 
(188-190). 
 
Cytotoxicity assay. Cells were seeded into 24-well plates at a density of 
2.5 x 104 (cells/well) and cultured under the indicated conditions. Cytotoxicity was 
assessed with crystal violet staining (170). Cells were fixed with 3.7% 
paraformaldehyde and stained with 1% crystal violet followed by washing with 
water to remove excess dye. The dye was solubilized with 2% SDS and the 
absorbance of the solubilized stain was measured at 590 nm using a Synergy HT 
Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The OD values were 
quantitated into the cell viability % by the formula, cell viability % = (OD value of 
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experimental group / OD value of control group) x 100%. The mock-control group 
was calculated as 100% of cell viability in the assay (171). 
 
Southern blot analysis. After viral infection, cells were collected at different time 
points. The viral DNA synthesis was determined with Southern blot; 1 µg of 
isolated genomic DNA was digested with the restriction enzyme PstI and analyzed 
with 1% agarose gel, which was subsequently transblotted to a Hybond-N+ 
membrane (YA3609; Amersham Pharmacia Biotech, Arlington Heights, IL). The 
probe was prepared by digesting 0.5 µg pBHGE3 (122) with PstI and labeled by 
following the protocol of Amersham AlkPhos Direct Labeling and Detection 
Systems (RPN 3690; GE Healthcare, Piscataway, NJ). The blot was 
prehybridized for 3 hrs at 63°C. The hybridization and stringency washes were 
performed at 60°C and followed by the chemiluminescent detection according to 
the manufacturer’s protocol. Densitometric value for the bands was quantified by 
Gel-pro Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) (191) and 
expressed as integrated optical density (I.O.D.). 
 
Western blot analysis. Infected cells were harvested at indicated time points and 
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium 
vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as 
described previously (123). Briefly, 60 µg of cell lysates were electrophoresed 
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P 
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Membrane (Millipore, Billerica, MA). The primary antibodies used in this study 
were rabbit anti-cyclin E (M-20), (Santa Cruz Biotechnology, Santa Cruz, CA), 
mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA), and rabbit 
anti-adenovirus type 5 antibody (Abcam, Cambridge, MA). Actin was used as an 
internal control. The membranes were then incubated with anti-mouse 
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific 
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection 
was performed with ECL reagents according to the supplier’s recommendations 
(GE Healthcare).  
 
Viral titration. Total infected cells and culture supernatants were collected at the 
indicated time points and lysed to release virus particles with three cycles of 
freezing and thawing. The viral titers were determined by the infective unit method 
as described previously (120, 121). Briefly, HEK 293 cells were seeded in 96-well 
plates at a density of 103 (cells/well) and then infected with 10-fold serially diluted 
viruses. CPE was recorded and scored after incubation for 7 days.  
 
Burst assay. Burst assay were used to determine the replication efficiency of 
human Ads in infected cells (192-194). Cells were seeded in 6-well plates at a 
density of 2 x 105 (cells/well) for 4 hr and infected with human Ads at 3.5 (for A549 
cells) or 10 MOI (for ED-1 cells). At 18 hr postinfection (p.i.) cell supernatants 
were removed and the cell monolayers were washed twice with PBS. At 18 hr and 
120 hr p.i., cells and supernatants were collected. The viral titers were determined 
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by the infective unit method. The burst ratio was expressed as the titer of virus at 
120 hr p.i. (virus output) relative to the titer of virus at 18 hr p.i. (virus input). An 
increase ratio in virus titer after 120 hours indicates virus replication. 
 
Statistical analyses. All above experiments, except specifically indicated, were 
repeated at least three times. Quantitation results were reported as means ± 
standard deviation (S.D.). Statistical difference of the combination experiment was 




Murine ED-1 cells show higher growth rate and lower serum sensitivity than 
human A549 cells. Human A549 and murine ED-1 lung cancer cell lines both 
have well-known backgrounds of the cyclin E expression. A549 cell line is the 
human lung cancer cell line with constitutive cyclin E expression and has been 
reported as a highly permissive cancer cell line for Ad oncolytic replication (56). 
ED-1 cell line was derived from transgenic mice with wild-type human cyclin E 
expression in lung cancers (88, 187). The growth characteristics of two cell lines 
were first compared in this study. Cells were cultured under 10% FBS and the cell 
proliferation of the two cell lines were determined by MTT assay. The final number 
of ED-1 cells increased 10-fold from day 0 to day 3, while A549 cells increased 
5.6-fold when cultured with 10% FBS (Fig. 4.1A). The doubling time generated 
from the data of cell growth in log phage indicated that the doubling time of ED-1 
cells is 18.6 hr and A549 is 30.17 hr, showing the growth rate of ED-1 cells is 
about 1.6-fold greater than that of A549 cells. Growth curves of A549 and ED-1 
cells in the presence of serum concentrations ranging from 0% to 10% were 
shown in Figure 3.1B. The results showed that proliferation of both cell lines were 
repressed under lower serum concentrations. The number of A549 cells cultured 
in medium with 0% serum only increased slightly, however ED-1 cells still 
managed to increase close to 4 fold under the same conditions (Fig. 4.1B). Thus, 
ED-1 cells grow significantly faster and exhibit less sensitivity to the decreased 























Figure 4.1. Growth characteristics of A549 and ED-1 cells. Cell proliferation 
and serum sensitivity of A549 and ED-1 cells were determined by MTT assay at 0, 
24, 48 and 72 hr. Cells were seeded into 24-well plates at a density of 2.5 x 104 
(cells/well) and cultured in (A) 10% FBS or (B) 0, 0.5, 1, 2.5, 5 and 10% FBS, 
respectively. The results were expressed as the fold change relative to the result 
at 0 hr. All values represent the means ± S.D. of independent triplicate.
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ED-1 cells require 3-fold higher titers of Ads to achieve similar infection 
efficiency as A549 cells. To maintain cells growth under a similar rate and 
density, A549 and ED-1 cells were cultured in 1% FBS and 0% FBS, respectively. 
Two approaches were applied to evaluate the infection efficiency of human Ads in 
A549 and ED-1 cells. First, we evaluated the Ad infection efficiency by quantifying 
the number of cells expressing GFP using a vector expressing a GFP reporter 
gene (AdGFP). A549 and ED-1 cells were infected with increasing MOI of AdGFP 
after seeding for 4 hr. For each infection, three random fields were taken by EVOS 
fluorescence microscope (AMG, Bothell, WA) at 72 hr p.i. (Fig. 4.2A). The number 
of GFP positive cells and the total cell numbers on each photo were counted with 
ImageJ (US National Institutes of Health, Bethesda, MD). The numbers of GFP 
positive cells were divided by total cell numbers on each photo to determine the 
infection efficiencies and presented in Figure 4.2B. Maximum infection of A549 
cells (90%) can be achieved by Ads with an MOI of 10, but ED-1 cells are required 
at least an MOI of 20. To have about 60% cell infected, an MOI of 10 is required 
for ED-1 cells and an MOI of 2.3 for A549 cells (Fig. 4.2B). 
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Figure 4.2. Infection efficiency of human adenoviruses on A549 and ED-1 
cells. A549 cells were cultured with 1% FBS and ED-1 cells were cultured with 
0% FBS at a density of 105 (cells/well). (A) The photographs were taken by EVOS 
fluorescence microscope (AMG, Bothell, WA) at 72 hr p.i. (B) The numbers of 
GFP cells on each photo were counted with ImageJ (US National Institutes of 
Health, Bethesda, MD). The results were expressed as GFP cell numbers relative 
to total cell numbers on the scene. All values represent the means ± S.D. of 
independent triplicate.
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Secondly, considering that promoter activity and GFP expression may differ from 
cell lines and interfere in determining the infection efficiency, we also used 
Southern blot to evaluate the infection efficiency by quantitating the amount of Ad 
DNA. As AdGFP is a non-replicative virus, the amounts of AdGFP DNA inside the 
cells should represent the amounts of virus DNA that entered into those cells 
initially. A549 and ED-1 cells were infected with AdGFP at increasing MOI. Cells 
were then harvested at 12 hr p.i. and the total DNA was isolated. The DNA 
samples were digested with PstI and then analyzed by Southern blot with Ad DNA 
fragments. Figure 4.3A represents the result of human AdGFP DNA entering ED-1 
and A549 cells. We observed that with the same MOI of AdGFP infection, Ad DNA 
amount entering ED-1 cells was lower than that entering A549 cells. Yet 
increasing infection MOI of AdGFP led to a concomitant increase of Ad DNA 
amount in both ED-1 and A549 cells, suggesting virus entry can be adjusted by 
altering the infection MOI of AdGFP. To compare the concentration of Ad DNA in 
ED-1 and A549 cells, we specifically determined the viral DNA densities in ED-1 
cells infected with 10 MOI and in A549 cells infected with 2.5, 5 and 10 MOI 
(boxed in Fig. 3A). Densitometric values for the bands were quantified by Gel-pro 
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) (191) and expressed 
as integrated optical density (I.O.D.) (Fig. 4.3B). The algorithmic result revealed 
that to achieve a similar infection with an MOI of 10 AdGFP for ED-1 cells, an MOI 
of 3.5 is required for A549 cells. In the following experiments, we chose 3.5 MOI 
of human Ad to infect human A549 cells and 10 MOI human Ad to infect murine 



















Figure 4.3. The DNA amounts of AdGFP entering cells. (A) A549 cells were 
cultured with 1% FBS and ED-1 cells were cultured with 0% FBS at a density of 
106 (cells/well) in 60 mm dishes. Cells were infected with AdGFP at 0, 1.25, 2.5, 5, 
10 and 20 MOI, respectively, and harvested at 24 hr p.i.. The DNA isolated from 
cells was totally loaded into the agarose gel. The amounts of AdGFP entering 
cells were quantitated by analyzing virus DNA amounts in cells with Southern blot. 
(B) Densitometric value for the bands was quantified by Gel-pro Analyzer 4.0 
software (Media Cybernetics, Bethesda, MD) and presented as integrated optical 
density (I.O.D.) values. 
 106 
Human oncolytic Ads are able to replicate in both murine and human lung 
cancer cell lines but poorly in noncancerous murine cell line. Murine 
NIH/3T3 cells generated from NIH Swiss mouse embryo fibroblasts (195) were 
applied here as a noncancerous control to compare with murine ED-1 lung cancer 
cell line. Relatively high levels of cyclin E expression was detected in human A549 
and murine ED-1 lung cancer cells but not in NIH/3T3 cells (Fig. 4.4A). The 
cytotoxicity of human Ads on cells were photographed and quantitated. AdGFP 
with deletion of E1 region was used as a non-replicative control. 
Replication-competent wild-type Ad5 (Adwt) and oncolytic dl1520 (ONYX-015) 
and Ad-cycE were chosen to evaluate the human Ad replication. Ad dl1520 is an 
attenuated adenovirus with E1b deletion which has been evaluated in several 
clinical studies (15, 17). Ad-cycE is an E1b-deleted oncolytic vector carrying a 
human cyclin E promoter driving E1A transcription to target lung cancers with 
cyclin E overexpression (169). To achieve equal infectivity, human A549 was 
mocked-infected or infected with AdGFP, dl1520 and Ad-cycE at 3.5 MOI and 
both murine ED-1 and NIH/3T3 cells were infected with various viruses at 10 MOI. 
The CPE became visible at 48-72 hr p.i., showing morphological change as 
infected cells rounded up and detached from the cell monolayer. Cytotoxicity or 
cell CPE caused by Ad infection was photographed with an inverted microscope 
(Olympus CKX41) (Fig. 4.4B). Mock-infection and non-replicative AdGFP 
infection did not induce cytotoxicity in cells. Adwt induced cytotoxicity in all cell 
lines with non-selectivity; however the two oncolytic viruses dl1520 and Ad-cycE 
only induced observed cytotoxicity on both A549 and ED-1 lung caner cells but 
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not on noncancerous NIH/3T3 cells. Cell viability was determined by crystal violet 
staining and then quantified by comparing each group to the mock-infected group 
(Fig. 4.4C). The results matched to the observations of virus CPE, suggesting the 








Figure 4.4. Cyclin E expression and cytopathic effects of human Ads on 
human A549, murine ED-1, and NIH/3T3 cells. (A) Cells were seeded in 60 mm 
dishes at a density of 106 for 18 hr and then collected. The cell lysates were 
immunoblotted for cyclin E protein and actin. Actin was used as a loading control. 
(B) Cells were mock-infected or infected with AdGFP, Adwt, dl1520 or Ad-cycE at 
3.5 MOI (for A549 cells) or 10 MOI (for ED-1 and NIH/3T3 cells). CPE was 
observed at 72 hr p.i and photographed with an inverted microscope Olympus 
CKX41. (C) The cell viability % was determined and the values represent the 
means ± S.D. of independent triplicate compared with the mock-infected group. 
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To determine whether the cytotoxicity was induced by complete virus replication in 
murine cells, burst assay was used to compare the virus output with virus input 
(192-194). Normally the burst ratio is generated by comparing virus production at 
72 hr (final virus output) to 4 hr (initial virus amount entering cells) and an 
increased ratio indicates virus replication. Considering human Ad infection for 4 hr 
caused very low infection efficiency in murine ED-1 cells, we chose 18 hr as the 
initial point and chose 120 hr at which the infected cells showed up complete CPE 
as the end point. Yields of Adwt, dl1520 and Ad-cycE increased 756-, 474-, and 
269-fold on average after infection in ED-1 cells, respectively. However, Ad titers 
only increased 25 fold for Adwt and 2 fold for dl1520 along with Ad-cycE in 
NIH/3T3 cells (Fig. 4.5). The burst ratio of Adwt in ED-1 is 30 times greater than 
that in NIH/3T3, and the burst ratio of oncolytic Ads were 100-200 fold increase 
























Figure. 4.5. Burst ratios of human Ad replication in ED-1 and NIH/3T3 cells. 
Cells were infected with Adwt, dl1520, and Ad-cycE at 10MOI for 18 hr or 120 hr. 
The virus yields were determine by infection unit method and expressed as burst 
ratios, representing virus yields at 120 hr p.i. relative to virus yields at 18 hr p.i.. 
The values represent the means ± S.D. of independent triplicate. 
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Wild-type and oncolytic human Ads replicate in both human and murine 
lung cancer cells. To further characterize the properties of human Ad replication 
in A549 and ED-1 cells, Ad DNA synthesis, E1A expression, the production of viral 
capsid proteins and the virus yields were analyzed. The viral DNA synthesis of 
human Ad was determined by Southern blot with the probes of Ad genomic DNA. 
As shown in Figure 4.6, mock-infected group did not contain viral DNA and the 
viral DNA level of non-replicative AdGFP was not detectable on the blot. Only in 
replication-competent Ad groups we detected viral DNA level which continuously 
increased from 24 hr to 48 hr p.i.. The results showed that Adwt, dl1520 and 
Ad-cycE can replicate in both human and murine lung cancer cells; oncolytic 
Ad-cycE can achieve the similar level as dl1520. The viral DNA synthesis level in 


























Figure. 4.6. Human Ad DNA synthesis in A549 and ED-1 cells. Virus DNA 
synthesis was determined by Southern blot. 3.5 MOI was used to infect A549 cells 
and 10MOI was used to infect ED-1 cells to achieve the similar infection efficiency. 
The DNA was isolated from the cells at 24 and 48 hr p.i. and fragmented with the 
restriction enzyme PstI. The probe was Adwt genome DNA. 
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The E1A expression level was examined by Western blot at 24 hr p.i. E1A is the 
crucial protein which is expressed immediately after infection and initiates the 
virus replication cycle (37). Ad E1A protein expression was examined at 24 hr and 
identified as multiple bands in the range of 35-46 kDa generated from the 
alternative splicing of E1A transcripts (196). As the pattern shown in human A549 
cells and murine ED1 cells, Ad E1A expression was only detected in the groups 
infected with replication-competent Adwt, dl1520 and Ad-cycE, but not in the 
groups mock-infected or infected with non-replicative AdGFP carrying the deletion 
of E1 region (Fig. 4.7A).  
 
The capsid protein production of human Ads in A549 and ED-1 was shown in 
Figure 4.7B. Consistent to the pattern of E1A expression, capsid protein 
production at 72 hr was detected in both human and murine cancer cells infected 
with replication-complete Adwt, dl1520 and Ad-cycE. To determine the virus 
production in both cell lines, virus yields were determined by the infection unit 
method and monitored over the time. Figure 4.7C revealed that virus yields of 
human Ads in murine ED-1 cells and human A549 cells increased over the time; 
the overall virus yield in ED-1 cells was 10-fold lower than that in human A549 
cells. The titers of Adwt, dl1520 and Ad-cycE produced by A549 cell culture at 72 
hr after infection increased to the range between 108 and 109 (IFU/ml); while the 
virus titers produced by ED-1 were between 107 and 108 (IFU/ml) (Fig. 4.7C). 
Taken all data together, we demonstrated that wild-type and oncolytic dl1520 and 













Figure 4.7. The expression of viral E1A, capsid protein and virus production 
in A549 and ED-1 cells. (A) Cells were mock-infected or infected with AdGFP, 
Adwt, dl1520 or Ad-cycE at 3.5 MOI (for A549 cells) or 10 MOI (for ED-1). Cells 
were collected at 24 hr p.i. and the cell lysates were immunoblotted for E1A 
protein and actin. (B) Infected cells were collected at 72 hr and the cell lysates 
were immunoblotted for viral capsid protein and actin. Actin was used as a loading 
control. (C) The virus yields were determined at 0, 24, 48, and 72 hr p.i. with the 




Adenovirus-mediated oncolysis is a novel approach for cancer therapy. Current 
animal experiments rely on immunodeficient mouse models with human xenograft 
tumors to evaluate the efficacy of oncolytic Ads. Due to the species specificity, 
human Ads tend to infect and replicate in human tumors rather than in murine 
tissues. Thus preclinical results obtained with human tumor xenografts in 
immunodeficient mouse models may overstate the therapeutic effects of oncolytic 
Ads. In addition, the patient’s immune responses may inhibit or augment oncolytic 
therapy. In this study, we compared Ad replication in murine and human lung 
cancer cells. We found that human Ads can penetrate and replicate in both 
murine and human lung cancer cells. When murine and human cancer cells are 
equally infected, viral DNA synthesis, early and late gene expression and virion 
production are observed with similar effects in both human and murine cells. 
Although with a lower production compared to human cells, human Ads can 
selectively replicate in and destroy murine cancer cells.  
 
Murine cells require a higher MOI of Ads to achieve same level infection as with 
human cancer cells. Entry of Ads into cells includes two well-known steps. The 
first step initiates from the high-affinity binding of adenovirus fiber knob to the 
coxsackievirus and adenovirus receptor (CAR) (197-200), followed by secondary 
interaction of the penton base with cell surface integrins to mediate the 
internalization of virus (201, 202). Human CAR is a transmembrane protein 
belonging to the immunoglobulin superfamily (203). The primary amino acid 
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sequences of human and murine CARs are highly homologous (203), thus the 
murine CAR may function as the key receptor for human Ad to enter murine cells. 
Besides murine CAR, cell surface integrins may be the other mediator for human 
Ad entry into the murine cells. Integrins are a family of cell-surface receptors for 
adhesion to extracellular matrix proteins or counter receptors on other cells (204). 
The RGD motif of the human Ad penton base serves as a recognition site for 
several human cellular integrins including αvβ3, αvβ5, αvβ1 andα3β1 (197, 
201, 204, 205). Studies have shown that some murine integrins share high 
homology with human integrins (206, 207). Additionally, heparan sulphate 
glycosaminoglycans (HS-GAGs) may play an important role in the cross-species 
infection of human Ad on murine cells. HS-GAGs have been shown to mediate 
CAR-independent attachment and infection by human Ads 2 and 5 in previous 
reports (208, 209). The basic motif of Lys-Lys-Thr-Lys (KKTK) on human Ad fiber 
shaft near the penton base was found to bind HS-GAGs (197, 210, 211). Raman 
et al. indicated that instead of murine CAR, mouse adenovirus type 1 utilizes 
cellular αv integrin and HS-GAGs as the primary receptors to enter murine cells 
(211). The infection of human Ads on murine ED-1 cells can be mediated via the 
known murine CAR, coreceptors such as integrins and heparan sulfate 
glycosaminoglycans or even by the other unknown pathways. 
 
Determinants of human Ad replication are also related to other steps of interaction 
with host cells. Once the human Ad particles are internalized into cells, viral 
replication in murine ED-1 lung cancer cells proceeds as in human A549 lung 
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cancer cells. We also compared human Ad replication in murine cancer cells and 
in noncancerous murine NIH/3T3 cells. Oncolytic Ads virions were produced at 
high levels in cancer ED-1 cells, but not in NIH/3T3 cells. Obviously, the entire 
human Ad life cycle can be completed in murine ED-1 lung cancer cells, but it is 
repressed in NIH/3T3 cells. It has been reported that human Ads normally 
undergo abortive replication but still can cause cell lysis in murine cells (212, 213). 
Virus yields of Ad2 and Ad5 in 3T3-Swiss and BALB/c 3T3 cells were reduced 3 to 
5 logs compared to virus production in human cells (214, 215), and no infectious 
virus particles of Ad12 were detected in murine 3T3 (embryo) and L (connective 
tissue) cells (213, 216). The block of human Ad replication in murine cells may be 
related to the low infectivity, unstable and reduced DNA synthesis, abortive 
expression of late proteins or the defective assembly and maturation at an later 
stage of viral replication cycle (213-218). Similar phenomenon was observed 
when we studied the human Ad replication in Chinese hamster ovary (CHO) cells. 
Even though we continuously observed that human wild-type Ad induces 
cytotoxicity on CHO cells, lack of late protein production appears to prevent 
infectious virion production in CHO cells (Cheng and Zhou, unpublished data). 
Our study shows that murine cancer ED-1 cells, but not noncancerous NIH/3T3, 
have the properties to allow human Ads to complete reproduction steps.  
 
While the exact mechanism(s) supporting the complete reproduction process of 
human Ads in murine cancer ED-1 cells remains to be investigated, it is tempting 
to speculate that the human cyclin E overexpression in the cell line may play an 
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important role. Cyclin E expression in murine ED-1 cells may support the virus 
reproduction process on multiple ways. Under the normal condition, cyclin E 
regulates cell cycle progression, DNA replication licensing (110, 111, 219), 
centrosome duplication (112, 113) and E2F activation (85). We previously 
demonstrated that human Ad replication relies on cyclin E induction by Ad 
E1B55K (56). Ad-induced cyclin E turns on the pRb/E2F pathways by activating 
CDK2 (164). It is possible that human Ad replication in murine ED-1 cells can be 
enhanced by cyclin E overexpression and/or any of cell proliferation alterations 
occurring in the carcinogenesis caused by the cyclin E overexpression. Potentially, 
ED-1 cells may be important to clarify the factors altered by cyclin E 
overexpression that allow cross-species replication of human Ads.  
 
In this report, we have shown that oncolytic Ads can selectively replicate in and 
destroy murine ED-1 cancer cells derived from the mouse lung adenocarcinomas. 
Currently we have inoculated FVB mice with ED-1 cells and are observing the 
formation of syngeneic mouse tumors in the animals. This study indicates that 
with murine cancer cells permissive for oncolytic Ad replication, it is feasible to 
establish syngeneic and immunocompetent mouse tumor models for preclinical 
studies that will better evaluate the anticancer effects of oncolytic Ads and predict 
therapeutic outcome in the clinical setting.
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CHAPTER V 
COMBINATION OF AUTOPHAGY INDUCER RAPAMYCIN AND ONCOLYTIC 
ADENOVIRUS IMPROVES ANTITUMOR EFFECT IN CANCER CELLS 
 
5.1. Introduction 
Oncolytic virotherapy with E1b55K-deleted adenoviruses (Ads) has been applied 
to human clinical trials in the United States and approved for the commercial use 
in China (18, 27, 32, 180, 220). The selective oncolytic effects can be achieved by 
a small quantity of viruses that spread to surrounding tumor cells, therefore 
contributing to an interesting drug platform (4, 153). Considering the viral tropism, 
respiratory oncolytic Ads should have a high potential for lung cancer therapy 
(221). However, lung cancer is generally difficult to treat with oncolytic viruses, 
and there are few recorded successful trials due to the cancer’s propensity to 
metastasize and the irregular shape of most tumors. Therefore, developing 
combination strategies to target human lung cancer with improved oncolytic Ads 
would allow for more effective treatment. 
 
In clinical treatments, oncolytic Ads are generally used with the first-line 
chemotherapy drugs, and the combination treatments have exhibited high 
therapeutic efficiency and improved safety (222). However, the interaction 
mechanism between chemotherapy drugs and viruses has not been well charac-
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terized. Selecting drugs for combination therapies based on the understanding of 
the interaction between Ads and drugs definitely will benefit the feasibility of this 
strategy. In our previous study, we have shown that the treatment of the 
autophagy inducer rapamycin increased the Ad yields and the autophagy inhibitor 
3-methyladenine (3-MA) reduced Ad replication (166). Our studies have also 
shown that autophagy may generate decomposed cellular molecules as nutrition 
to support Ad replication. Thus, an autophagy inducer may improve virus oncolytic 
therapy. 
 
Autophagy is a process involving the lysosomal degradation and recycling of 
cellular proteins and cytoplasmic organelles (178). Environment stressors such as 
nutrient starvation and pathogen infection induce autophagy. Autophagy initiates 
from membrane structures called phagophores (178, 223, 224), which engulf 
cellular and cytoplasmic components, followed by elongation and recruitment of 
microtubule-associated protein 1 light chanin 3 (LC3) to form the characteristic 
double-membrane autophagosome. Cytoplasmic form LC3-I and lipidated form 
LC3-II are two forms of LC3 post-transcriptionally produced in cells (225-227). 
LC3 is immediately processed into LC3-I after synthesis. During the autophagy 
process, LC3-I is cleaved by cysteine protease Atg4 to generate lipidated form 
LC3-II that localizes on autophagosome membranes (224, 228). The amount of 
LC3-II or the LC3-II/LC3-I ratio can be used to estimate the degree of 
autophagosome formation (225, 226, 229). Autophagosomes eventually fuse into 
lysosomes to form autolysosomes, in which the inner components undergo the 
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degradation process and produce amino acids and fatty acids for reuse in cells. 
Rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR) (230, 
231), has been shown to induce autophagy and inhibit proliferation of malignant 
glioma cells (232). Autophagy is negatively regulated by the PI3K-AKT-mTOR 
pathway. Via inhibiting the negative regulation of mTOR signaling, rapamycin 
indirectly enhances autophagy.  
 
Using a tumor-specific promoter to regulate Ad E1A expression is a general effort 
to control selective replication of vectors in cancer cells and cause oncolysis. The 
proteins encoded by the E1a region, expressed immediately after infection, then 
modulate the cell cycle, recruit cellular proteins, and produce viral proteins to 
process viral DNA replication (37). However, all known tumor-specific promoters 
are relative weak compared with the native promoter of the Ad E1a gene (159, 
161). In addition, Ad infection can cause strong repression of most cellular 
promoters, as indicated in our published microarray study (79). Vectors driven by 
tumor-specific promoters generally elicit low potency and do not work as 
efficiently as dl1520, which contains the native E1a promoter and is applied in 
current tumor treatments (159, 161). However, the native E1a promoter does not 
exhibit selectivity and therefore has side effects, such as virus replication in 
noncancerous cells (155, 156). Obviously, the selection of promoters in vector 
construction should consider the negative effects imposed by virus infection on 
those promoters. We thus have constructed a novel E1b-deleted oncolytic 
Ad-cycE, in which Ad E1a gene is driven by the cyclin E promoter. Cyclin E is 
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known to regulate DNA replication and promote the S-phase entry (110, 111). 
Cyclin E overexpression is frequently detected in many types of cancers, 
including lung cancer (87). Recent studies also showed that overexpression of 
cyclin E can trigger lung cancers in transgenic mice (86, 115). Our previous 
studies revealed that the replication of E1b55K-deleted Ads is significantly 
repressed in G0-arrested normal cells (56, 123), in which the cyclin E promoter is 
restricted. We have also demonstrated that the activity of cyclin E promoter in 
cancer cells is further augmented after Ad infection (56, 165). As the replication of 
E1b-deleted Ad-cycE depends on the activation of cyclin E promoter, Ad-cycE 
replication may be enhanced in cancer cells and repressed in normal cells.  
 
In this study, we applied novel tumor-specific Ad-cycE and rapamycin in 
combination to enhance oncolytic effects. We show that Ad-cycE is competent to 
replicate in human lung cancer cells but not in the normal lung cells and that the 
combination of oncolytic Ad-cycE and the autophagy inducer rapamycin elicits 
synergistic inhibition effects. We also reveal that rapamycin increases Ad E1A 
expression and virus production. Our studies have clearly shown that autophagy 
inducers as chemotherapeutic agents are capable of increasing adenoviral 
replication and oncolysis. Thus the combination of autophagy-associated 
chemotherapy and oncolytic virotherapy may be a new approach to improve 
future cancer treatment.  
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5.2. Materials and Methods 
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), WI-38 
human lung fibroblast (ATCC no. CCL-75), MCF10A human mammary epithelial 
(ATCC no. CRL-10317), MDA-MB-231 human breast cancer (ATCC no. HTB-26), 
A549 (ATCC no. CCL-185) and H1299 (ATCC no. CRL-5803) human lung cancer 
cell lines were purchased from the American Type Culture Collection (Rockville, 
MD). WI-38 human lung fibroblast cell line has the properties of primary cells with 
a finite lifetime of 50 population doublings (174). MCF10A human mammary 
epithelial cell line is an immortalized but non-transformed human breast epithelial 
cell line (233, 234). WI-38 cells were cultured in minimal essential medium (MEM) 
Alpha GlutaMAX with 0.1 mM non-essential amino acids and 1.0 mM sodium 
pyruvate. MCF10A cells were cultured in DMEM/F12K with 20ng/ml EGF, 
0.5μg/ml Hydrocortisone, and 10μg/ml insulin. HEK 293, A549 and MDA-MB-231 
cells were cultured in DMEM. All media were supplemented with 5% (for MCF10A 
cells) or 10% (for the other cells) fetal bovine serum (FBS) and 
penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at 
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD).  
 
Adenoviral vectors. Figure 5.1 depicts the structures of the adenoviruses 
applied in this study. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was 
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1 
deletion carrying a green fluorescent protein (GFP), was used as a 
replication-defective control (164). Ad-cycE is a novel E1b-deleted oncolytic 
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vector carrying a human cyclin E promoter driving an intact E1A expression 
cassette. The endogenous E1a promoter was deleted and a human cyclin E 
promoter (GenBank ID: X95406 (168)) was inserted to replace the deleted E1a 
promoter in Ad-cycE. Therefore, Ad-cycE contains a human cyclin E promoter to 
control E1a open reading frames (ORF). The details of Ad-cycE construction will 
be reported separately in our preparing report. All of the vectors created and used 












Figure 5.1. Structure of the Ads. The wild-type Ad (Adwt) with the E1a and E1b 
genes and their endogenous promoters is shown at the top. The left inverted 
terminal repeat (ITR), the promoters for E1a gene and E1b genes (E1a-P and 
E1b-P) and the E1a and E1b open reading frames are indicated. The solid lines 
represent Adwt regions in these viruses, and the dashed lines represent the 
deleted regions. AdGFP contains the complete deletion of E1a and E1b regions 
and their promoters. Ad-cycE contains the deletion of E1b region and a cyclin E 
promoter (cycE-P) was inserted to replace the deleted E1a promoter. 
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Cytotoxicity assay. Cells were seeded into 24-well plates at a density of 
2.5 x 104 (cells/well) and cultured under the indicated conditions. After 72 hours, 
Cytotoxicity was assessed with crystal violet staining (170). Cells were fixed and 
stained with 1% crystal violet followed by washing with water to remove excess 
dye. The dye was solubilized with 2% SDS and the absorbance of the solubilized 
stain was measured at 590 nm using a Synergy HT Multi-Mode Microplate Reader 
(Bio-Tek, Winooski, VT). The OD values were quantitated into the cell viability % 
by the formula, cell viability % = (OD value of experimental group / OD value of 
control group) x 100%. Rapamycin and viruses were diluted with corresponding 
culture media. The 0 nM control group was treated with the diluents and was 
calculated as 100% of cell viability in the assay (171). 
 
Analyses of combination effects of rapamycin and Ad-cycE. In this study, an 
additive effect refers to a combined effect of drugs that produces the sum of their 
individual effects; synergism is the combined effect of drugs which is greater than 
the sum of individual effects, and antagonism is the combined effect of drugs 
which is less than the sum of individual effects (235, 236). The combined effects 
of rapamycin and Ad-cycE on cell viability were analyzed with the median-effect 
methods of Chou and Talalay (237) using CalcuSyn software (Biosoft, Ferguson, 
MO). The combination index (CI) values were used to evaluate the interaction 
between the drug and virus. For the fraction of virus affected combination index 
(Fa-CI) plot analysis, a CI < 1 is defined as synergism, a CI = 1 is defined as an 
additive effect, and a CI > 1 is defined as antagonism. The data were confirmed 
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with the isobologram method (238, 239). The diagonal curves connecting the x- 
and y-axes were calculated from single treatments to represent the additive effect 
for the theoretical combinations of two treatments at the specific effective doses. If 
the data points fall on the lower left of the diagonal, the combination is regarded 
as synergism. If the experimental data points of the drug combination fall on the 
diagonal, the combination is regarded as an additive effect. If the data points fall 
on the upper right of the diagonal, the combination is regarded as antagonism. 
 
Viral titration. Cells were seeded into 6-well plates at a density of 2 x 105 
(cells/well) and treated under the indicated conditions. Total infected cells and 
culture supernatants were collected at 48 hr postinfection (p.i.) and lysed to 
release virus particles with three cycles of freezing and thawing. The viral yields 
were determined by the infective unit method as described previously (120, 121). 
HEK 293 cells were seeded in 96-well plates at a density of 103 (cells/well) and 
then infected with 10-fold serially diluted viruses. CPE was recorded and scored 
after incubation for 7 days.  
 
Western blot analysis. Cells were harvested and lysed with CDK2 lysis buffer 
(20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5% Nonidet P-40, 0.1% Brij 35, 
5 mM sodium glycerophosphate, 1 mM sodium vanadate, 1 mM dithiothreitol). 
The Western blot analyses were performed as described previously (123). 25 µg 
of cell lysates were electrophoresed through 10 or 12% SDS-polyacrylamide gels 
and transferred onto an Immobilon-P Membrane (Millipore, Billerica, MA). The 
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primary antibodies used in this study were rabbit anti-LC3 and actin (Sigma, St. 
Louis, MO), mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA), 
and rabbit anti-adenovirus type 5 antibody (Abcam, Cambridge, MA). Actin was 
used as an internal control. The membranes were then incubated with anti-mouse 
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific 
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection 
was performed with ECL reagents according to the supplier’s recommendations 
(GE Healthcare). The scanned band intensity was quantitated by Gel-pro 
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) according to the 
manufacturer’s tutorial. Densitometric value for each band was expressed as 
integrated optical density (I.O.D.) and normalized with actin. The results were 
reported as the ratios of normalized band intensities of LC3-II to LC3-I. 
 
Statistical analyses. All above experiments, except specifically indicated, were 
repeated at least three times. Quantitation results were reported as means ± 
standard deviation (S.D.). The Pearson correlation coefficient (r) was used to 
evaluate the correlations between the rapamycin concentrations and cell viability 
percentages by SAS software, Version 9.3 (SAS Institute Inc., Cary, NC) (240, 
241). Statistical difference of the combination experiment was assessed with a 
Student's t-test. Statistical significance of difference was set at p < 0.05. 
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5.3. Results 
Selective replication of Ad-cycE in cancer cells. Figure 5.1 depicts the 
structures of the adenoviruses applied in this study. Adwt was used as a 
replication-competent control. AdCMV/GFP, a vector with E1a and E1b deletion 
carrying a green fluorescent protein (GFP), was used as a replication-defective 
control. Our previous reports indicated that the cyclin E promoter is more active in 
lung cancer cells than in normal lung cells and oncolytic E1b-deleted Ad infection 
further elevates the promoter activation (56, 165). Thus, we replaced the native 
E1a promoter with the cyclin E promoter to generate Ad-cycE, a novel 
E1b-deleted oncolytic vector.  
 
To determine the selectivity of Ad-cycE for cancer cells, we first examined the 
cytotoxicity of Ad-cycE on normal and cancer cell lines. WI-38 human lung 
fibroblast, MCF10A mammary epithelial, A549 and H1299 lung cancer and 
MDA-MB-231 breast cancer cells were infected with AdGFP, Adwt or Ad-cycE at 5 
MOI. Ad-cycE replicated in A549 and H1299 human lung cancer, and 
MDA-MB-231 breast cancer cells and caused cytopathic effect (CPE) similar to 
that of Adwt (Fig. 5.2A, comparing panel hr and i, k and l, n and o). The CPE 
became visible at 48 hr and 72 hr p.i., showing that the infected cells became 
circular and detached from the cell monolayer. Unlike Adwt, which 
indistinguishably induced CPE in noncancerous WI-38 human lung fibroblast and 
MCF10A mammary epithelial cells, Ad-cycE selectively induced CPE in all tested 
cancer cells (Fig. 5.2A, comparing panel b and c, e and f).   
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WI-38, A549 and H1299 cells were infected with Adwt or Ad-cycE at 5 MOI and 
the total infected cells and culture supernatants were collected at 72 hr to 
examine the production of infectious virus particles. Figure 5.2B revealed that in 
noncancerous WI-38 human lung fibroblast cells, the virus yield of Adwt was 
significantly higher than that of Ad-cycE (P = 0.04); in H1299 human lung cancer 
cells, there was no significant difference between the virus yield of Adwt and 
Ad-cycE (P = 0.2); in A549 human lung cancer cells, Adwt (3.7 X 109) and 
Ad-cycE (8.3 X 108) achieved a high level of virus yield, indicating the replication 
property of Ad-cycE in lung cancer cells. The aggregated data from this 
experiment shows that Ad-cycE can selectively replicate in and efficiently destroy 
cancer cells but poorly replicates in noncancerous cells. 
Previous studies indicate that replication-competent oncolytic Ads could produce 
the essential Ad E1 proteins to support the replication of replication-defective 
E1-deleted Ads co-transduced in vitro or in vivo (165, 242, 243). To further verify 
selective replication capability of Ad-cycE in cancer cells, A549 human lung 
cancer cell line with constitutive cyclin E production (56) was chosen for the 
following experiment. A549 cells were infected with 5MOI AdGFP alone, or 
AdGFP plus an additional Ad (AdGFP+AdlacZ, AdGFP+Adwt or 
AdGFP+Ad-cycE). Figure 5.2C showed that the non-replicative AdGFP 
maintained the original level of infectivity at day 1 and day 2 (compare panels a 
and b). Also, with coinfection of AdGFP and non-replicative AdlacZ, the 
fluorescent cell numbers did not change (compare panels c and d). Yet with the 
addition of Adwt (compare panels e and f) or Ad-cycE (compare panels g and h), 
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we detected an increase of fluorescent cell numbers from day 1 to day 2, 
suggesting that efficacy of Ad-cycE replication in cancer cells is comparable with 







Figure 5.2. Selective oncolytic replication of Ad-cycE. (A) WI-38, MCF10A, 
A549, H1299 and MDA-MB-231 cells were infected with AdGFP, Adwt, or Ad-cycE 
at 5 MOI. CPE was observed at 48 hr or 72 hr p.i and photographed with an 
inverted microscope Olympus CKX41. (B) Viral yields produced in WI-38, H1299 
and A549 cells were determined at 72 hr p.i. with the infection unit method. The 
values represent the means ± S.D. of independent triplicate. * P<0.05, Student’s 
t-test. (C) A549 cells were co-infected with 5 MOI AdGFP and mock-infection, 
AdlacZ, Adwt or Ad-cycE. All fluorescent microscopy is taken at day 1 and day 2 
p.i. with an Olympus IX50 microscope (original magnification of X100).   
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Rapamycin induces autophagy and inhibits lung cancer cell growth. 
Rapamycin has been shown to induce autophagy and inhibit proliferation of 
malignant glioma cells (232). We investigated whether rapamycin can induce 
autophagy in A549 lung cancer cells. The cells were treated with 0 nM, 100 nM, 
and 200 nM rapamycin for 24 hr. Western blot was used to determine the 
conversion of LC3-I to LC3-II, which is one of the representative characteristics of 
autophagy activation. LC3 is immediately processed into LC3-I after synthesis. 
Then the cytoplasmic form LC3-I is cleaved by cysteine protease Atg4 to generate 
lipidated form LC3-II that specifically localizes to autophagosome membranes 
(228). Thus the amount of LC3-II or the LC3-II/LC3-I ratio can be applied to 
estimate the abundance of autophagosomes (225, 226, 229). Figure 5.3A shows 
two forms of LC3, the upper band corresponding to LC3-I and lower band 
corresponding to LC3-II (225). Compared with the 0 nM-control group (the ratio of 
LC3-II/LC3-I = 0.82), the 100 nM and 200 nM rapamycin treatments increased the 
amount of LC3-II and caused the ratio of LC3-II/LC3-I to 2.75 and 2.88, 
respectively, indicating the induction of autophagy. Next we examined the effect of 
rapamycin on A549 cell growth. The cells were treated with 0 nM, 100 nM, 200 nM, 
400 nM, 600 nM and 800 nM rapamycin for 72 hr. The cell viability was 
determined with crystal violet staining and quantitated into cell viability 
percentages. The results showed that rapamycin decreased cell viability in a 
dose-dependent manner at 72 hr compared to the 0 nM-control group (r = 



















Figure 5.3. Effects of rapamycin on cytotoxicity and autophagy. A549 cells 
were treated with 0 nM, 100 nM, and 200 nM ramamycin (LC Laboratories, 
Woburn, MA) and collected at 24 hr after treatment. (A) Cell lysates were 
immunoblotted for LC3 and actin. Actin was used as a loading control. The values 
indicate the ratios of normalized band intensities of LC3-II to LC3-I. (B) A549 cells 
were treated with 0 nM, 100 nM, 200 nM, 400 nM, 600 nM and 800 nM ramamycin. 
The cell viability % was determined at 72 hr after treatment. The values of cell 
viability % represent the means ± S.D. of independent quadruplicate compared 
with the 0 nM-control group. 
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Combination of rapamycin and Ad-cycE elicits stronger cytotoxicity than 
single treatment alone. We first chose 200 nM rapamycin as the working 
condition and tested the combination effects of rapamycin with different MOIs of 
Ad-cycE on lung cancer cell growth. Figure 5.4A shows a difference between the 
cell viability percentage of treatment with Ad-cycE alone and Ad-cycE in 
combination with rapamycin. Our results show that Ad-cycE in combination with 
rapamycin induces greater CPE in A549 lung cancer cells than either treatment 
alone. The distinction can be clearly seen in both 0.5 MOI Ad-cycE and 1 MOI 
Ad-cycE. Statistical Student's t-tests confirmed the significant difference. 
Treatments with 200 nM rapamycin or 1 MOI Ad-cycE both resulted in the cell 
viability of about 50% (53.9% for rapamycin and 52% for Ad-cycE). Combination 
of Ad-cycE and rapamycin decreased cell viability to 23.6% (P = 0.00000011). We 
repeated the experiment with even lower dose of Ad-cycE (0.5 MOI), which only is 
able to induce slight CPE. 0.5MOI Ad-cycE only caused 73.9% of the cell viability 
(P = 0.0052), but combination with 200 nM rapamycin caused 39.4% of the cell 
viability (P = 0.0000000002). The cell morphology was photographed with an 
inverted microscope on day 2 (Fig 5.4B). These results suggest that rapamycin in 
combination with Ad-cycE elicits greater cytotoxicity on A549 cells even with a low 






















Figure 5.4. Effects of combination of rapamycin and Ad-cycE on A549 cells. 
A549 cells were non-treated or treated with 200 nM rapamycin alone, 0.5 or 1 
MOI Ad-cycE alone, or the combination treatment of 200 nM rapamycin and 0.5 or 
1 MOI Ad-cycE. (A) The results were quantitated into cell viability %. The values 
of cell viability % represent the means ± S.D. of independent triplicate compared 
with the mock-control group. * P<0.05, Student’s t-test. (B) CPE was 
photographed at a magnification of X100 at 48 hr p.i. 
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Rapamycin increases Ad E1A expression and oncolytic replication. The 
stronger antitumor effect in the combination treatment may be generated from the 
sum of the effect of two individual treatments or even a synergistic effect (one 
treatment may increase the efficacy of the other). To understand the mechanism 
by which rapamycin in combination with Ad-cycE caused stronger antitumor 
effects, we first examined the production of virus particles, comparing virus alone 
with the combination groups. Rapamycin treatment led to a 4.25-fold increase in 
virus yield compared to the virus alone group (Fig. 5.5A). This suggests that 
rapamycin increases the production of Ad-cycE in A549 cells, resulting in stronger 
antitumor effects than either drug or virus alone. Next we examined the E1A 
expression to determine the mechanism by which rapamycin may contribute to 
the increased production of Ad vectors. E1A is the crucial protein which is 
expressed immediately after infection and initiates the virus replication cycle (37). 
Ad E1A protein expression was examined at 18 hours and identified as multiple 
bands at 35-46 kDa generated from the alternative splicing of E1A transcripts 
(196). As shown in Figure 5.5B, rapamycin stimulates elevated E1A expression in 
the combination group when compared to Ad-cycE alone. Taken together, the 
results suggest that rapamycin increases oncolytic replication of Ad-cycE in A549 






















Figure 5.5. Effects of rapamycin on the oncolytic replication of Ad-cycE. 
A549 cells were non-treated or treated with 200 nM rapamycin alone, 0.5 MOI 
Ad-cycE alone, combination treatment of 200 nM rapamycin and 0.5 MOI Ad-cycE. 
(A) Viral yields were determined at 48 hr p.i. with the infection unit method. The 
values represent the means ± S.D. of independent triplicate. (B) Cell lysates 
harvested at 18 hr p.i. were immunoblotted for Ad E1A and actin. Actin was used 
as a loading control.
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Combination of rapamycin and Ad-cycE elicits synergistic antitumor effects. 
To determine whether combination of rapamycin and Ad-cycE produce synergistic 
antitumor effects, we evaluated the combination treatments with Calcusyn (Biosoft, 
Ferguson, MO). The combination experiment was performed by adopting the 
constant ratio drug combination design proposed by Chou and Talalay (237). 
A549 human lung cancer cells were treated with rapamycin alone (from 100 nM to 
700 nM), Ad-cycE alone (from 0.5 MOI to 3.5 MOI) or a combination of rapamycin 
(nM) with Ad-cycE (MOI) at the constant ratio of 200:1 for 96 hr. Concordant with 
the results shown in Figure 5.4, combination of rapamycin and Ad-cycE caused a 
greater cytotoxicity than either treatment alone (Fig. 5.6A). We then evaluated 
these quantitated data by fraction affected versus combination index (Fa-Cl) with 
CalcuSyn software (Biosoft, Ferguson, MO) (Fig. 5.6B). The X-marks represent 
the combination index (CI) values of the combination treatment groups. The CI 
values are 0.326, 0.512, 0.506, 0.642, and 0.689 for 100 nM rapamycin plus 0.5 
MOI Ad-cycE, 200 nM rapamycin plus 1 MOI Ad-cycE, 300 nM rapamycin plus 1.5 
MOI Ad-cycE, 600 nM rapamycin plus 3 MOI Ad-cycE, and 700 nM rapamycin 
plus 3.5 MOI Ad-cycE, respectively. The middle curve line represents the 
simulated combination index values of the combination treatment groups 
surrounded by two lines of algebraic estimations of the 95% confidence intervals. 
All experimental CI values at the tested ratio were significantly < 1 and between 
the two confidence lines, indicating synergism of combination treatments.  
 
Since rapamycin and Ad treatments have entirely independent modes of action, 
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the conservative isobologram method (237, 244) was also applied here to confirm 
the above Fa-Cl results. The effective concentration EC50, EC75 and EC90 refer to 
the concentration of a drug or the combination of the two drugs that induces 50%, 
75% and 90% inhibition of cell viability (236). Figure 5.6C shows the conservative 
isobologram plots of EC50, EC75 and EC90, separately. In the conservative 
isobologram plot, the curve connecting each axis indicates the simulated additive 
effect for EC50, EC75 and EC90, respectively. The experimental EC50, EC75 and 
EC90 doses of the combination treatment groups are displayed as the single point 
indicated by the arrow. The point values of the EC50, EC75 and EC90 for the 
combination treatments all fall below their diagonal lines for simulated additive 
effects, indicating that significantly lower doses of rapamycin and Ad-cycE are 
therapeutically effective when combined. For example, in EC50 isobologram, from 
the simulated curve of the additive effect it shows that to reach 50% inhibition of 
cell viability requires at least 800 nM rapamycin or 1 MOI Ad-cycE. However, with 
the combination of rapamycin and Ad-cycE it takes a relatively low dose (50 nM 
rapamycin plus 0.25 MOI Ad-cycE) to achieve the same efficacy, suggesting 
combination treatment elicits a greater effect (synergism) than an additive effect. 
These results in Figure 5.6A, B and C have all demonstrated that the combination 
of rapamycin with Ad-cycE elicits a synergistic antitumor effect in A549 human 





Figure 5.6. Analysis by Calcusyn (Biosoft, Ferguson, MO) of the interaction 
between rapamycin and Ad-cycE on A549 cells. Cells were treated with 
rapamycin alone, Ad-cycE alone or combination of both for 96 hr. (A) The results 
were quantitated into cell viability %. The values of cell viability % represent the 
means ± S.D. of independent triplicate compared with the mock-control group. (B) 
The quantitated cell viability data were analyzed by CalcuSyn software. The 
X-marks represent the combination index (CI) values of the combination 
treatment groups. The middle curve line represents the simulated combination 
index values of the combination treatment groups surrounded by two lines of 
algebraic estimations of the 95% confidence intervals. (C) The effective 
concentration EC50, EC75 and EC90 refer to the concentration of a drug or 
combination of drugs that induces 50%, 75% and 90% inhibition of cell viability. In 
the conservative isobologram plot, the three curves of the expected EC50, EC75 
and EC90 additive effect lines for the combination treatments are labeled; the 
individual points of EC50, EC75 and EC90 for the combination treatments were 
indicted by arrows and located below their additive interaction lines, respectively.  
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In addition, we examined the combination effect of rapamycin and Ad-cycE on 
MDA-MB-231 human breast cancer cell line, which has been reported as a 
non-permissive cancer cell line for oncolytic Ads replication (56). As we observed 
in A549 cells, the combination of rapamycin and Ad-cycE induced a greater 
cytotoxicity than either treatment alone in MDA-MB-231 cells (Fig. 5.7A) and the 
therapeutic effect was significantly enhanced by the synergism of combination 






















Figure 5.7. Effects of combination of rapamycin and Ad-cycE on 
MDA-MB-231 cells. (A) Cells were treated with rapamycin alone, Ad-cycE alone 
or combination of both for 96 hr. The results were quantitated into cell viability %. 
The values of cell viability % represent the means ± S.D. of independent triplicate 
compared with the mock-control group. (B) The quantitated cell viability data were 
analyzed by CalcuSyn software. In the fraction affected versus combination index 
(Fa-CI) plot, all experimental CI values at the tested ratio were significantly < 1 
and within the confidence lines.
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To determine whether the findings with rapamycin and oncolytic Ad-cycE may 
apply to wild-type Ad, we tested the same conditions with the combination of 
rapamycin and Adwt. Consistent to the results shown in Figure 5.6 and 5.7, 
combination of rapamycin and Adwt also caused a greater cytotoxicity than either 
treatment alone (Fig. 5.8A). Fa-Cl plot showed that all CI values at the tested 
concentration ratio were significantly < 1 and between the two confidence lines, 
suggesting the synergism of rapamycin and Adwt (Fig. 5.8B). Our data indicated 
that the synergism is not only observed in the combination of rapamycin and 
oncolytic Ad-cycE but also in that of rapamycin and Adwt, suggesting the potential 
















Figure 5.8. Effects of combination of rapamycin and wild-type Ad on A549 
cells. (A) Cells were treated with rapamycin alone, Adwt alone or combination of 
both for 72 hr. The results were quantitated into cell viability %. The values of cell 
viability % represent the means ± S.D. of independent triplicate compared with the 
mock-control group. (B) The quantitated cell viability data were analyzed by 
CalcuSyn software. In the fraction affected versus combination index (Fa-CI) plot, 





Oncolytic virotherapy has shown promising therapeutic results and is considered 
a potential approach for cancer therapy (245). The matchless advantage of this 
approach is that selective oncolytic effects are initiated by a small amount of 
viruses that spread to the surrounding regions until all cancer cells are destroyed 
(4). However, due to the current limitations, virus replication and diffusion are 
restricted in animal studies and clinical trials when the objectives carry tumors 
with large masses (17, 121, 246). Viruses have difficulty penetrating massive 
tumors; this may be a reason for disappointing therapeutic outcomes. Developing 
new strategies to increase virus propagation in tumors is important in improving 
the efficiency of oncolytic virotherapy.  
 
In our previous study we have shown that autophagy may generate decomposed 
cellular molecules as nutrients to support virus replication (166). Therefore we 
applied the autophagy inducer rapamycin to develop a combination strategy with 
oncolytic Ad-cycE. First, rapamycin-caused autophagy can generate more 
nutrients that can be used for building the viral particles (166, 247). Second, 
autophagy may increase virus particle release from dead cells that may benefit 
viral spread in tumors (248). Third, rapamycin has been applied to transplant 
recipients as an immunosuppressant to prevent organ rejection (249). The 
immunosuppressive properties of rapamycin mainly result from the inhibition of 
leukocyte activity and cytokine expression. Thus, rapamycin as an 
immunosuppressant may help virus to decrease host antiviral responses and 
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improve virus distribution in tumors. Finally, autophagy-induced cell death has 
been applied as the new target in chemotherapy (250). Thus the antitumor effects 
can be enhanced by both rapamycin-caused autophagy and virus-mediated 
oncolysis.  
 
We demonstrated that Ad-cycE selectively replicated in cancer cells. Ad-cycE in 
combination with autophagy-inducer rapamycin further induced synergistic 
antitumor effects. Rapamycin may also improve oncolytic therapy mediated by 
other viruses. Studies have shown that an autophagy mechanism is required for 
hepatitis B virus replication (251), the initiation of hepatitis C virus replication (252) 
and the promotion of viral replication of the RNA viruses such as poliovirus and 
rhinovirus (253). The new role of autophagy to help the virions of adenovirus type 
2 (Ad2) to traffic in cells has also been discovered in a recent study (247). After 
the virus has been internalized into cells, high level of autophagosomes induced 
by autophagy are reported to fuse with the early endosomes containing virions 
and form amphisomes, creating an environment favoring the release of virions 
into cytosol. Here, we specifically observed that the autophagy inducer rapamycin 
increased the E1A expression and led to higher Ad-cycE production. In 
agreement with our finding, Zeng and Carlin (2013) reported that 
starvation-induced autophagy enhanced the E1A expression and the viral 
progeny production of Ad2 in human airway epithelial cells (247). E1A is the 
crucial protein expressed immediately after infection and regulates the expression 
of multiple cellular and viral genes to initiate the virus replication cycle (37). 
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Therefore, we reasoned that autophagy is not only able to generate nutrients for 
building viral particles, but is also able to increase the E1A expression of Ads, 
leading to higher virus production and the enhanced combination therapeutic 
effects.  
 
mTOR pathway has been considered as a determinant regulator in the cellular 
metabolism (254). The mTOR inhibitor rapamycin has been reported to elicit 
diverse and paradoxical effects on the cellular metabolism. Some studies 
suggested that rapamycin decreases glucose metabolism (255-257) and 
mitochondrial oxidative functions in mammalian cells (258, 259), whereas some 
others suggested that rapamycin increases glycolysis and oxidative 
phosphorylation in the targeted cells (260, 261). Fang et al. (2013) pointed out 
that although detrimental metabolic changes were observed at early stages of 
rapamycin treatment in mice, the prolonged rapamycin treatment leaded to 
beneficial metabolic alterations, including increased insulin sensitivity, improved 
lipid profile and metabolism (262). Apparently, the discrepancy of those metabolic 
alternations by rapamycin likely depends on the natures of signaling pathways 
activated in the cell lines and the duration of treatment (261, 262). Under this 
circumstance, the relation between the metabolic alterations induced by mTOR 
inhibition and the adenoviral replication still remains unclear. Some DNA viruses 
such as adenovirus and human cytomegalovirus stimulate metabolic alternations 
such as glycolysis in the host cells to generate energy and essential elements for 
viral replication (263-265). Besides autophagy, the property of rapamycin to 
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induce metabolic changes may be also utilized by adenovirus to create a 
beneficial environment for the viral replication. 
 
Based on our previous work with the chemical CDK2 inhibitor roscovitine (164), 
we noticed that some chemotherapeutic agents with the kinase inhibition 
properties may inhibit oncolytic Ad replication and thus impair the outcome of 
oncolytic virotherapy in the combination therapy. It is important to select the 
chemotherapeutic agents without negative effects on oncolytic viruses when 
conducting the combination therapy. mTOR regulates several essential signal 
transduction pathways including the control of cell-cycle progression (254). As an 
mTOR inhibitor, one of the key functions of rapamycin is to inhibit cell-cycle 
progression (266). Rapamycin is reported to decrease cyclin D1 expression (267), 
reduce the kinase activity of cyclin D1/CDK4 and cyclin E/CDK2 complexes (268), 
and block the elimination of the CDK inhibitor p27 (269), leading to cell cycle 
arrest in G1-S-phase (266). The mechanism(s) by which oncolytic adenoviruses 
overcome the cell cycle arrest by rapamycin-induced mTOR inhibition requires the 
further study. Considering the possible negative effects of rapamycin on cell 
cyclins and cell-cycle progression, autophagy is likely to conduct a very important 
role for the rapamycin-enhanced virus replication in this study. 
 
Our studies suggest a novel strategy involving targeting cyclin E overexpression 
in cancer cells and the properties of autophagy to enhance adenoviral oncolysis 
that could have a significant impact on clinical outcomes in cancer therapy. The 
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combination of Ad-cycE and rapamycin can be further tested in vivo to evaluate 
the efficacy and efficiency for the clinical setting. Our findings also provide 
important information for future adenoviral vector development and the 
combination study for improving oncolytic virotherapy. 
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CHAPTER VI 
SUMMARY AND FUTURE PERSPECTIVES 
 
Although E1b55K-deleted oncolytic Ads has been applied in many clinical trials 
and marketed for cancer therapies in China, the mechanism enabling tumor 
selectivity of the viruses still remains controversial. The lack of understanding of 
selective replication of E1b55K-deleted Ads limits further development of the 
oncolytic virotherapy in cancer patients. Our goal is to fill these gaps and to obtain 
valuable information to benefit virotherapy. Previously we have demonstrated that 
cyclin E plays a critical role in adenovirus replication and deregulation of cyclin E 
expression in cancer cells is the molecular basis of selective replication of the 
oncolytic Ads. In this dissertation we further develop the mechanism model and 
extended the knowledge achieved from this model to the virtual application in the 
design of a novel tumor-specific oncolytic Ad. 
 
Initial studies, shown in Chapter II, have demonstrated the role of cyclin E 
participates in oncolytic Ad replication through activation of CDK2; generating a 
suitable environment for viral replication. Ad E1B55K mediates cyclin E induction 
for viruses to efficiently replicate in normal cells. This E1B55K function is not 
critically required for the viral replication in cancer cells due to the deregulated 
cyclin E expression or having E1B55K-like cancer cellular factors, thus allowing 
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preferential replication of E1b55K-deleted Ads in cancer cells. Ad-induced cyclin 
E binds to and activates CDK2 that subsequently phosphorylates the 
transcriptional suppressor pRb, which can regulate expression of multiple cellular 
and viral genes, including cyclin E itself. (The work has been published in PLoS 
ONE 8(2): e57340.) 
 
The work presented in Chapter III focuses on characterization of the replication 
profile of oncolytic virus Ad-cycE in human lung cancer cells. Cyclin E promoter is 
highly active in cancer cells and its activity is further enhanced after Ad infection. 
We utilized the dual properties of cyclin E promoter and have constructed a novel 
E1b-deleted Ad-cycE in which Ad E1A is driven by human cyclin E promoter as a 
novel therapeutic agent. Ad-cycE exhibits potent antitumor efficacy in vitro and in 
vivo and thus prolongs the survival time of mice bearing lung cancer xenograft. As 
cyclin E is highly deregulated in numerous cancers and further augmented during 
virus multiplication, oncolytic Ad-cycE represents tumor specificity and has the 
possibility to overcome restriction in nonpermissive cancer cells for dl1520. (The 
manuscript is in preparation.) 
 
In Chapter IV, we extended our studies from human lung cancer cells to evaluate 
the oncolytic efficacy of Ad-cycE with murine lung cancer cells. Our data showed 
that Ad-cycE can selectively replicate in and destroy murine ED-1 cancer cells 
derived from the mouse lung adenocarcinomas. Thus ED-1 is identified as a 
permissive murine lung cancer cell line for oncolytic Ad replication. We have 
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evaluated the oncolytic efficacy of Ad-cycE with the syngeneic ED-1 mouse 
tumors in the immunocompetent FVB mice. (The manuscript is in preparation.) 
 
As shown in Chapter V, the impact of combination treatment with Ad-cycE and 
rapamycin which induces autophagy in lung cancer was explored based on the 
hypothesis that autophagy enhances oncolytic replication of Ad-cycE. Ad-cycE in 
combination with autophagy-inducer rapamycin has been shown to induce 
synergistic antitumor effects. Our data suggest this strategy involving in targeting 
cyclin E overexpression in cancer cells and enhanced autophagy could have a 
significant impact on clinical outcomes in cancer therapy. (The work has been 
published in Virology Journal 10(1):293) 
 
The work presented in this dissertation has addressed the question, “By which 
mechanism does cyclin E contribute to oncolytic viral replication in cancer cells?” 
and revealed the potential of Ad-cycE for clinical application. Our work also raises 
a number of interesting directions for future research in the field of oncolytic 
virotherapy.  
 
First, cancer cells with cyclin E deregulation may provide E1B55K-like factors to 
allow the cyclin E induction by E1b55K-deleted oncolytic Ads to overcome the 
growth restriction; however what kinds of cancer cellular factors existing in 
permissive cancer cells for this function are still unclear. Future study can focus 
on identifying the E1B55K-like factors existing in cancer cells and characterizing 
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the following application to improve oncolytic virotherapy.  
 
Second, our studies in the novel oncolytic Ad driven by cyclin E promoter have 
illuminated an attractive potential for this approach with dual properties to target 
both cancer tumorigenesis and virus-induced intracellular environment change. 
Transcriptionally controlling viral genes or other therapeutic genes with the human 
cyclin E promoter can be expected as feasible. Future vectors may combine this 
strategy with the other strategies, such as genetic modification on viral fibers or 
arming the virus with cytokine or anticancer genes. The new-generation tumor 
specific adenoviruses, with enhanced transduction efficiency and immunity 
stimulation, may increase cancer killing effects and improve therapeutic outcomes 
from oncolytic virotherapy. 
 
Third, we have identified a novel permissive murine lung cancer cell line for 
oncolytic Ad replication. A future orthotopic lung cancer model in 
immunocompetent syngeneic mouse model should be developed using these 
murine lung cancer cells to better evaluate oncolytic virotherapy in a more 
patient-like setting and study the role of immune responses in oncolytic 
virotherapy. Further preclinical studies on pharmacodynamics, pharmacokinetics 
and the toxicity of oncolytic Ads with rodent and non-rodent models should also 
be investigated before Ad-cycE and the other similar Ad vectors can be applied to 
human clinical trials. 
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Additionally, we observed the synergistic antitumor effects elicited by applying 
combination strategy with novel Ad-cycE and an autophagy inducer rapamycin in 
vitro. The future in vivo studies should be included to evaluate the benefit for 
clinical application. Another area of the field that bears further attention is to 
identify more potent autophagy inducers rather than only using the prototype drug 
rapamycin for this combination strategy. A screening test of combination effects of 
oncolytic Ads with novel autophagy inducers such as Spermidine (270), 
Saikosaponin-d (271) and GTM-1 (272) can be designed and conducted to select 
more efficient candidates to achieve improved outcomes. We believe that the 
future progression in oncolytic adenovirology, along with various improvements in 
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3-MA   3-methyladenine 
Ad    adenovirus  
Adwt   wild-type adenovirus 
ATG   autophagy-related protein 
BCL-2   B-cell lymphoma 2 
CPE   cytopathic effect 
CDC25   cell division cycle 25 
CDK2   cyclin-dependent kinase 2 
CHO   Chinese hamster ovary  
CAR   coxsackievirus and adenovirus receptor  
cyclin EL  large form of cyclin E 
CLS   centrosomal localization signal 
CTLs   cytotoxic T lymphocytes 
CI    combination index 
DNA   deoxyribonucleic acid 
DMSO   dimethyl sulfoxide  
EC    effective concentration 
FBS   fetal bovine serum  
Fa-CI   fraction of virus affected combination index
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GFP   green fluorescent protein  
hTERT   human telomerase reverse transcriptase 
HS-GAGs  heparan sulphate glycosaminoglycans 
IP    immunoprecipitation 
IFU    infectious unit 
IgG    immunoglobulin G 
I.O.D   integrated optical density 
ITR    inverted terminal repeat 
LC3    microtubule-associated protein 1 light chanin 3 
MDM2   mouse double minute 2 homolog 
mRNA   messenger ribonucleic acid 
MCM   minichromosome maintenance protein 
MLP   major late promoter 
mTOR   mammalian target of rapamycin 
MOI    multiplicity of infection 
MEM-Alpha  minimal essential medium Alpha 
ORF   open reading frame 
OD    optical density 
PBS   phosphate buffered saline 
Rb    retinoblastoma gene 
pRb       retinoblastoma protein 
phospho-pRb    phosphorylated pRb 
PCNA   proliferating cell nuclear antigen 
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p.i.    post infection 
PSA    prostate-specific antigen 
Ros    roscovitine 
siRNA   small interfering ribonucleic acid 
S.D.   standard deviation 
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